Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,32988509,area under the concentration-time curve between zero and the last sampling point (AUC0→t),"Despite the fact that all of the studied antimicrobials were administered at an identical IV dose, the area under the concentration-time curve between zero and the last sampling point (AUC0→t) for MIN (35,014 ± 3,274 μg × hour/mL) and CTC (41,851 ± 10,965 μg × hour/mL) differed significantly from that determined for TIG (18,866 ± 4,326 μg × hour/mL) and TET (17,817 ± 4,469 μg × hour/mL).","Comparative pharmacokinetics of chlortetracycline, tetracycline, minocycline, and tigecycline in broiler chickens. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988509/),[h·μg] / [ml],"35,014",535,DB01017,Minocycline
,32988509,area under the concentration-time curve between zero and the last sampling point (AUC0→t),"Despite the fact that all of the studied antimicrobials were administered at an identical IV dose, the area under the concentration-time curve between zero and the last sampling point (AUC0→t) for MIN (35,014 ± 3,274 μg × hour/mL) and CTC (41,851 ± 10,965 μg × hour/mL) differed significantly from that determined for TIG (18,866 ± 4,326 μg × hour/mL) and TET (17,817 ± 4,469 μg × hour/mL).","Comparative pharmacokinetics of chlortetracycline, tetracycline, minocycline, and tigecycline in broiler chickens. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988509/),[h·μg] / [ml],"41,851",536,DB01017,Minocycline
,32988509,area under the concentration-time curve between zero and the last sampling point (AUC0→t),"Despite the fact that all of the studied antimicrobials were administered at an identical IV dose, the area under the concentration-time curve between zero and the last sampling point (AUC0→t) for MIN (35,014 ± 3,274 μg × hour/mL) and CTC (41,851 ± 10,965 μg × hour/mL) differed significantly from that determined for TIG (18,866 ± 4,326 μg × hour/mL) and TET (17,817 ± 4,469 μg × hour/mL).","Comparative pharmacokinetics of chlortetracycline, tetracycline, minocycline, and tigecycline in broiler chickens. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988509/),[h·μg] / [ml],"18,866",537,DB01017,Minocycline
,32988509,area under the concentration-time curve between zero and the last sampling point (AUC0→t),"Despite the fact that all of the studied antimicrobials were administered at an identical IV dose, the area under the concentration-time curve between zero and the last sampling point (AUC0→t) for MIN (35,014 ± 3,274 μg × hour/mL) and CTC (41,851 ± 10,965 μg × hour/mL) differed significantly from that determined for TIG (18,866 ± 4,326 μg × hour/mL) and TET (17,817 ± 4,469 μg × hour/mL).","Comparative pharmacokinetics of chlortetracycline, tetracycline, minocycline, and tigecycline in broiler chickens. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988509/),[h·μg] / [ml],"17,817",538,DB01017,Minocycline
,32988509,AUC0→t,"After IV administration, the values of AUC0→t were also directly related to total body clearance values which were significantly higher for TIG (0.56 ± 0.14 L/hour × kg) and TET (0.60 ± 0.14 L/hour × kg) than for CTC (0.25 ± 0.05 L/hour × kg) and MIN (0.29 ± 0.03 L/hour × kg).","Comparative pharmacokinetics of chlortetracycline, tetracycline, minocycline, and tigecycline in broiler chickens. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988509/),[l] / [h·kg],0.56,539,DB01017,Minocycline
,32988509,AUC0→t,"After IV administration, the values of AUC0→t were also directly related to total body clearance values which were significantly higher for TIG (0.56 ± 0.14 L/hour × kg) and TET (0.60 ± 0.14 L/hour × kg) than for CTC (0.25 ± 0.05 L/hour × kg) and MIN (0.29 ± 0.03 L/hour × kg).","Comparative pharmacokinetics of chlortetracycline, tetracycline, minocycline, and tigecycline in broiler chickens. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988509/),[l] / [h·kg],0.60,540,DB01017,Minocycline
,32988509,AUC0→t,"After IV administration, the values of AUC0→t were also directly related to total body clearance values which were significantly higher for TIG (0.56 ± 0.14 L/hour × kg) and TET (0.60 ± 0.14 L/hour × kg) than for CTC (0.25 ± 0.05 L/hour × kg) and MIN (0.29 ± 0.03 L/hour × kg).","Comparative pharmacokinetics of chlortetracycline, tetracycline, minocycline, and tigecycline in broiler chickens. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988509/),[l] / [h·kg],0.25,541,DB01017,Minocycline
,32988509,AUC0→t,"After IV administration, the values of AUC0→t were also directly related to total body clearance values which were significantly higher for TIG (0.56 ± 0.14 L/hour × kg) and TET (0.60 ± 0.14 L/hour × kg) than for CTC (0.25 ± 0.05 L/hour × kg) and MIN (0.29 ± 0.03 L/hour × kg).","Comparative pharmacokinetics of chlortetracycline, tetracycline, minocycline, and tigecycline in broiler chickens. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988509/),[l] / [h·kg],0.29,542,DB01017,Minocycline
,32988509,total body clearance,"After IV administration, the values of AUC0→t were also directly related to total body clearance values which were significantly higher for TIG (0.56 ± 0.14 L/hour × kg) and TET (0.60 ± 0.14 L/hour × kg) than for CTC (0.25 ± 0.05 L/hour × kg) and MIN (0.29 ± 0.03 L/hour × kg).","Comparative pharmacokinetics of chlortetracycline, tetracycline, minocycline, and tigecycline in broiler chickens. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988509/),[l] / [h·kg],0.56,543,DB01017,Minocycline
,32988509,total body clearance,"After IV administration, the values of AUC0→t were also directly related to total body clearance values which were significantly higher for TIG (0.56 ± 0.14 L/hour × kg) and TET (0.60 ± 0.14 L/hour × kg) than for CTC (0.25 ± 0.05 L/hour × kg) and MIN (0.29 ± 0.03 L/hour × kg).","Comparative pharmacokinetics of chlortetracycline, tetracycline, minocycline, and tigecycline in broiler chickens. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988509/),[l] / [h·kg],0.60,544,DB01017,Minocycline
,32988509,total body clearance,"After IV administration, the values of AUC0→t were also directly related to total body clearance values which were significantly higher for TIG (0.56 ± 0.14 L/hour × kg) and TET (0.60 ± 0.14 L/hour × kg) than for CTC (0.25 ± 0.05 L/hour × kg) and MIN (0.29 ± 0.03 L/hour × kg).","Comparative pharmacokinetics of chlortetracycline, tetracycline, minocycline, and tigecycline in broiler chickens. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988509/),[l] / [h·kg],0.25,545,DB01017,Minocycline
,32988509,total body clearance,"After IV administration, the values of AUC0→t were also directly related to total body clearance values which were significantly higher for TIG (0.56 ± 0.14 L/hour × kg) and TET (0.60 ± 0.14 L/hour × kg) than for CTC (0.25 ± 0.05 L/hour × kg) and MIN (0.29 ± 0.03 L/hour × kg).","Comparative pharmacokinetics of chlortetracycline, tetracycline, minocycline, and tigecycline in broiler chickens. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988509/),[l] / [h·kg],0.29,546,DB01017,Minocycline
,32988509,bioavailability,"In turn, after PO administration, TIG was absorbed in only 1.55% ± 0.82, and CTC in 30.54% ± 6.99, whereas the bioavailability of MIN and TET was relatively high at 52.33% ± 3.92 and 56.45% ± 9.71, respectively.","Comparative pharmacokinetics of chlortetracycline, tetracycline, minocycline, and tigecycline in broiler chickens. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988509/),%,52.33,547,DB01017,Minocycline
,32988509,bioavailability,"In turn, after PO administration, TIG was absorbed in only 1.55% ± 0.82, and CTC in 30.54% ± 6.99, whereas the bioavailability of MIN and TET was relatively high at 52.33% ± 3.92 and 56.45% ± 9.71, respectively.","Comparative pharmacokinetics of chlortetracycline, tetracycline, minocycline, and tigecycline in broiler chickens. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988509/),%,56.45,548,DB01017,Minocycline
,27245381,m,The ion transitions under ESI positive model were performed at m/z 586.3 > 513.2 and m/z 595.3 > 514.3 for TGC and d9-TGC internal standard (IS).,Development and validation of an LC-MS/MS method for the determination of tigecycline in human plasma and cerebrospinal fluid and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27245381/),,58,1722,DB01017,Minocycline
,27245381,m,The ion transitions under ESI positive model were performed at m/z 586.3 > 513.2 and m/z 595.3 > 514.3 for TGC and d9-TGC internal standard (IS).,Development and validation of an LC-MS/MS method for the determination of tigecycline in human plasma and cerebrospinal fluid and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27245381/),,513.2,1723,DB01017,Minocycline
,27245381,m/z,The ion transitions under ESI positive model were performed at m/z 586.3 > 513.2 and m/z 595.3 > 514.3 for TGC and d9-TGC internal standard (IS).,Development and validation of an LC-MS/MS method for the determination of tigecycline in human plasma and cerebrospinal fluid and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27245381/),,59,1724,DB01017,Minocycline
,27245381,m/z,The ion transitions under ESI positive model were performed at m/z 586.3 > 513.2 and m/z 595.3 > 514.3 for TGC and d9-TGC internal standard (IS).,Development and validation of an LC-MS/MS method for the determination of tigecycline in human plasma and cerebrospinal fluid and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27245381/),,514.3,1725,DB01017,Minocycline
,27245381,AUC0-12,"The AUC0-12 in plasma and CSF calculated according to our noncompartment model were 4713 and 23,0238 h ng/mL, respectively.",Development and validation of an LC-MS/MS method for the determination of tigecycline in human plasma and cerebrospinal fluid and its application to a pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27245381/),[h·ng] / [ml],4713,1726,DB01017,Minocycline
,27245381,AUC0-12,"The AUC0-12 in plasma and CSF calculated according to our noncompartment model were 4713 and 23,0238 h ng/mL, respectively.",Development and validation of an LC-MS/MS method for the determination of tigecycline in human plasma and cerebrospinal fluid and its application to a pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27245381/),[h·ng] / [ml],"23,0238",1727,DB01017,Minocycline
,10423658,elimination half-lives at beta-phase,"The elimination half-lives at beta-phase averaged 25.0 +/- 16.4 hours, the volume of distribution averaged 32.9 +/- 13.4 L, and the total clearance averaged 1.14 +/- 0.49 L/h.",Pharmacokinetic characteristics of minocycline in debilitated elderly patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423658/),h,25.0,2796,DB01017,Minocycline
,10423658,volume of distribution,"The elimination half-lives at beta-phase averaged 25.0 +/- 16.4 hours, the volume of distribution averaged 32.9 +/- 13.4 L, and the total clearance averaged 1.14 +/- 0.49 L/h.",Pharmacokinetic characteristics of minocycline in debilitated elderly patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423658/),l,32.9,2797,DB01017,Minocycline
,10423658,total clearance,"The elimination half-lives at beta-phase averaged 25.0 +/- 16.4 hours, the volume of distribution averaged 32.9 +/- 13.4 L, and the total clearance averaged 1.14 +/- 0.49 L/h.",Pharmacokinetic characteristics of minocycline in debilitated elderly patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423658/),[l] / [h],1.14,2798,DB01017,Minocycline
,28264853,MIC,"Specifically, we investigated the relationship between minocycline exposure and bactericidal activity using five A. baumannii isolates with a broad range of susceptibility (MIC ranged from 0.25 mg/liter to 16 mg/liter).",Pharmacokinetics and Pharmacodynamics of Minocycline against Acinetobacter baumannii in a Neutropenic Murine Pneumonia Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28264853/),[mg] / [l],0.25,3730,DB01017,Minocycline
,28264853,MIC,"Specifically, we investigated the relationship between minocycline exposure and bactericidal activity using five A. baumannii isolates with a broad range of susceptibility (MIC ranged from 0.25 mg/liter to 16 mg/liter).",Pharmacokinetics and Pharmacodynamics of Minocycline against Acinetobacter baumannii in a Neutropenic Murine Pneumonia Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28264853/),[mg] / [l],16,3731,DB01017,Minocycline
,28264853,AUCELF,"The required AUCELF,0-24/MIC for maintaining stasis and achieving 1-log-unit reduction were 140 and 410, respectively.",Pharmacokinetics and Pharmacodynamics of Minocycline against Acinetobacter baumannii in a Neutropenic Murine Pneumonia Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28264853/),,140,3732,DB01017,Minocycline
,28264853,0-24/MIC,"The required AUCELF,0-24/MIC for maintaining stasis and achieving 1-log-unit reduction were 140 and 410, respectively.",Pharmacokinetics and Pharmacodynamics of Minocycline against Acinetobacter baumannii in a Neutropenic Murine Pneumonia Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28264853/),,410,3733,DB01017,Minocycline
,23883872,urine recovery,"The serum concentration-time profiles and exposures were similar in the obese-C3 and NW adults, with a mean urine recovery of 15.8% and 13.4%, respectively.",Serum and urine pharmacokinetics of tigecycline in obese class III and normal weight adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23883872/),%,15.8,8334,DB01017,Minocycline
,23883872,urine recovery,"The serum concentration-time profiles and exposures were similar in the obese-C3 and NW adults, with a mean urine recovery of 15.8% and 13.4%, respectively.",Serum and urine pharmacokinetics of tigecycline in obese class III and normal weight adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23883872/),%,13.4,8335,DB01017,Minocycline
,23883872,AUC0-∞,"The median (range) AUC0-∞ was 8.19 (6.12, 11.2) and 7.50 (6.78, 9.13) mg · h/L in the obese-C3 and NW groups, respectively.",Serum and urine pharmacokinetics of tigecycline in obese class III and normal weight adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23883872/),[h·mg] / [l],8.19,8336,DB01017,Minocycline
,23883872,AUC0-∞,"The median (range) AUC0-∞ was 8.19 (6.12, 11.2) and 7.50 (6.78, 9.13) mg · h/L in the obese-C3 and NW groups, respectively.",Serum and urine pharmacokinetics of tigecycline in obese class III and normal weight adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23883872/),[h·mg] / [l],7.50,8337,DB01017,Minocycline
≥,23883872,AUC0-∞ : MIC target,"The CFR was calculated to be <90% against Acinetobacter baumannii, Enterobacter cloacae and Klebsiella pneumoniae for an AUC0-∞ : MIC target ≥ 6.96.",Serum and urine pharmacokinetics of tigecycline in obese class III and normal weight adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23883872/),,6.96,8338,DB01017,Minocycline
,10722495,elimination half-lives,"Pharmacokinetic studies demonstrated dose-dependent elimination half-lives of 1.05 to 2.34 and 1.65 to 3.36 h and serum protein bindings of 59 and 71% for GAR-936 and WAY 152,288, respectively.","In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722495/),h,1.05 to 2.34,11067,DB01017,Minocycline
,10722495,elimination half-lives,"Pharmacokinetic studies demonstrated dose-dependent elimination half-lives of 1.05 to 2.34 and 1.65 to 3.36 h and serum protein bindings of 59 and 71% for GAR-936 and WAY 152,288, respectively.","In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722495/),h,1.65 to 3.36,11068,DB01017,Minocycline
,10722495,serum protein bindings,"Pharmacokinetic studies demonstrated dose-dependent elimination half-lives of 1.05 to 2.34 and 1.65 to 3.36 h and serum protein bindings of 59 and 71% for GAR-936 and WAY 152,288, respectively.","In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722495/),%,59,11069,DB01017,Minocycline
,10722495,serum protein bindings,"Pharmacokinetic studies demonstrated dose-dependent elimination half-lives of 1.05 to 2.34 and 1.65 to 3.36 h and serum protein bindings of 59 and 71% for GAR-936 and WAY 152,288, respectively.","In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722495/),%,71,11070,DB01017,Minocycline
,33975336,fAUC/MIC,The minocycline fAUC/MIC for 24 h static effect and -1 log drop in bacterial load were 12.5 ± 7.1 and 23.3 ± 12.4.,The pharmacodynamics of minocycline alone and in combination with rifampicin against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33975336/),,12.5,11415,DB01017,Minocycline
,33975336,fAUC/MIC,The minocycline fAUC/MIC for 24 h static effect and -1 log drop in bacterial load were 12.5 ± 7.1 and 23.3 ± 12.4.,The pharmacodynamics of minocycline alone and in combination with rifampicin against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33975336/),,23.3,11416,DB01017,Minocycline
,33975336,fAUC/MIC,An fAUC/MIC minocycline target of 12-36 is appropriate for S. aureus.,The pharmacodynamics of minocycline alone and in combination with rifampicin against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33975336/),,12-36,11417,DB01017,Minocycline
,19738006,MICs,"Six S. aureus isolates were studied, and the TGC MICs for those isolates ranged from 0.125 to 0.5 mg/liter.",Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19738006/),[mg] / [l],0.125 to 0.5,22066,DB01017,Minocycline
,19738006,half-life,TGC displayed linear PK and had a mean half-life of 10.9 +/- 2.5 h.,Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19738006/),h,10.9,22067,DB01017,Minocycline
,19738006,80%,"The 80% and 50% effective exposure indexes and the stasis exposure index were similar between the isolates (means +/- standard deviations, 3.04 +/- 1.12, 1.84 +/- 1.3, and 1.9 +/- 1.5, respectively).",Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19738006/),,3.04,22068,DB01017,Minocycline
,19738006,50%,"The 80% and 50% effective exposure indexes and the stasis exposure index were similar between the isolates (means +/- standard deviations, 3.04 +/- 1.12, 1.84 +/- 1.3, and 1.9 +/- 1.5, respectively).",Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19738006/),,3.04,22069,DB01017,Minocycline
,19738006,effective exposure,"The 80% and 50% effective exposure indexes and the stasis exposure index were similar between the isolates (means +/- standard deviations, 3.04 +/- 1.12, 1.84 +/- 1.3, and 1.9 +/- 1.5, respectively).",Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19738006/),,3.04,22070,DB01017,Minocycline
,19738006,stasis exposure index,"The 80% and 50% effective exposure indexes and the stasis exposure index were similar between the isolates (means +/- standard deviations, 3.04 +/- 1.12, 1.84 +/- 1.3, and 1.9 +/- 1.5, respectively).",Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19738006/),,1.84,22071,DB01017,Minocycline
,19738006,stasis exposure index,"The 80% and 50% effective exposure indexes and the stasis exposure index were similar between the isolates (means +/- standard deviations, 3.04 +/- 1.12, 1.84 +/- 1.3, and 1.9 +/- 1.5, respectively).",Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19738006/),,1.9,22072,DB01017,Minocycline
,20921312,area under the concentration-time curve from 0 to 24 h (fAUC(0-24)),"The mean values for the plasma, thigh, and wound free area under the concentration-time curve from 0 to 24 h (fAUC(0-24)) were 2.65 ± 0.33, 2.52 ± 1.15, and 2.60 ± 1.02 μg·h/ml, respectively.",Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20921312/),[h·μg] / [ml],2.65,24762,DB01017,Minocycline
,20921312,area under the concentration-time curve from 0 to 24 h (fAUC(0-24)),"The mean values for the plasma, thigh, and wound free area under the concentration-time curve from 0 to 24 h (fAUC(0-24)) were 2.65 ± 0.33, 2.52 ± 1.15, and 2.60 ± 1.02 μg·h/ml, respectively.",Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20921312/),[h·μg] / [ml],2.52,24763,DB01017,Minocycline
,20921312,area under the concentration-time curve from 0 to 24 h (fAUC(0-24)),"The mean values for the plasma, thigh, and wound free area under the concentration-time curve from 0 to 24 h (fAUC(0-24)) were 2.65 ± 0.33, 2.52 ± 1.15, and 2.60 ± 1.02 μg·h/ml, respectively.",Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20921312/),[h·μg] / [ml],2.60,24764,DB01017,Minocycline
,20921312,steady-state tissue concentrations,"Mean steady-state tissue concentrations for the thigh and wound were similar at 0.12 ± 0.02 μg/ml, and clearance from the tissues appeared similar to that from plasma.",Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20921312/),[μg] / [ml],0.12,24765,DB01017,Minocycline
,20921312,Tissue penetration ratios (tissue fAUC/plasma fAUC),Tissue penetration ratios (tissue fAUC/plasma fAUC) were 99% in the thigh and 100% in the wound (P = 0.964).,Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20921312/),%,99,24766,DB01017,Minocycline
,20921312,Tissue penetration ratios (tissue fAUC/plasma fAUC),Tissue penetration ratios (tissue fAUC/plasma fAUC) were 99% in the thigh and 100% in the wound (P = 0.964).,Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20921312/),%,100,24767,DB01017,Minocycline
,20705929,half-life,Pharmacokinetic analysis (n=22) revealed a half-life of approximately 24 hours and linearity of parameters over doses.,Minocycline to improve neurologic outcome in stroke (MINOS): a dose-finding study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20705929/),h,24,25184,DB01017,Minocycline
,20705929,half-life,"The half-life of minocycline is approximately 24 hours, allowing every 24-hour dosing.",Minocycline to improve neurologic outcome in stroke (MINOS): a dose-finding study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20705929/),h,24,25185,DB01017,Minocycline
,25150050,maximum concentrations,"The maximum concentrations were found within 1 h after the end of the intravenously given tigecycline, and were 1,308.60 ± 301.76 ng/mL in plasma, 181.40 ± 51.32 ng/mL in vitreous humor and 145.00 ± 55.29 ng/mL in aqueous humor of the inflamed eye.",Pharmacokinetics of intravenously administered tigecycline in eye compartments: an experimental study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25150050/),[ng] / [ml],"1,308.60",27338,DB01017,Minocycline
,25150050,maximum concentrations,"The maximum concentrations were found within 1 h after the end of the intravenously given tigecycline, and were 1,308.60 ± 301.76 ng/mL in plasma, 181.40 ± 51.32 ng/mL in vitreous humor and 145.00 ± 55.29 ng/mL in aqueous humor of the inflamed eye.",Pharmacokinetics of intravenously administered tigecycline in eye compartments: an experimental study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25150050/),[ng] / [ml],181.40,27339,DB01017,Minocycline
,25150050,maximum concentrations,"The maximum concentrations were found within 1 h after the end of the intravenously given tigecycline, and were 1,308.60 ± 301.76 ng/mL in plasma, 181.40 ± 51.32 ng/mL in vitreous humor and 145.00 ± 55.29 ng/mL in aqueous humor of the inflamed eye.",Pharmacokinetics of intravenously administered tigecycline in eye compartments: an experimental study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25150050/),[ng] / [ml],145.00,27340,DB01017,Minocycline
,782466,serum levels,After i.v. infusion of 200 mg minocycline (during 1 h) mean serum levels fell from 3.5 mug/ml to 0.6 mug/ml (after 24 h).,[Activity in vitro and pharmacokinetics of minocycline (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/782466/),[μg] / [ml],3.5,32218,DB01017,Minocycline
,782466,serum levels,After i.v. infusion of 200 mg minocycline (during 1 h) mean serum levels fell from 3.5 mug/ml to 0.6 mug/ml (after 24 h).,[Activity in vitro and pharmacokinetics of minocycline (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/782466/),[μg] / [ml],0.6,32219,DB01017,Minocycline
,782466,Half-life,"Half-life was calculated as 15.7 h, urine recovery as 5.9%.",[Activity in vitro and pharmacokinetics of minocycline (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/782466/),h,15.7,32220,DB01017,Minocycline
,782466,urine recovery,"Half-life was calculated as 15.7 h, urine recovery as 5.9%.",[Activity in vitro and pharmacokinetics of minocycline (author's transl)]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/782466/),%,5.9,32221,DB01017,Minocycline
,782466,serum level peaks,"After oral application of 200 mg minocycline serum level peaks were 2.7 mug/ml, serum levels after 24 h 0.7 mug/ml.",[Activity in vitro and pharmacokinetics of minocycline (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/782466/),[μg] / [ml],2.7,32222,DB01017,Minocycline
,782466,serum levels,"After oral application of 200 mg minocycline serum level peaks were 2.7 mug/ml, serum levels after 24 h 0.7 mug/ml.",[Activity in vitro and pharmacokinetics of minocycline (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/782466/),[μg] / [ml],0.7,32223,DB01017,Minocycline
,782466,CSF,CSF levels after oral administration of 0.4 g minocycline were 0.74 +/- 0.09 mug/ml (in serum at the same time 2.2 +/- 0.2 mug/ml).,[Activity in vitro and pharmacokinetics of minocycline (author's transl)]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/782466/),[μg] / [ml],0.74,32224,DB01017,Minocycline
,782466,CSF,CSF levels after oral administration of 0.4 g minocycline were 0.74 +/- 0.09 mug/ml (in serum at the same time 2.2 +/- 0.2 mug/ml).,[Activity in vitro and pharmacokinetics of minocycline (author's transl)]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/782466/),[μg] / [ml],2.2,32225,DB01017,Minocycline
,782466,levels,CSF levels after oral administration of 0.4 g minocycline were 0.74 +/- 0.09 mug/ml (in serum at the same time 2.2 +/- 0.2 mug/ml).,[Activity in vitro and pharmacokinetics of minocycline (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/782466/),[μg] / [ml],0.74,32226,DB01017,Minocycline
,782466,levels,CSF levels after oral administration of 0.4 g minocycline were 0.74 +/- 0.09 mug/ml (in serum at the same time 2.2 +/- 0.2 mug/ml).,[Activity in vitro and pharmacokinetics of minocycline (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/782466/),[μg] / [ml],2.2,32227,DB01017,Minocycline
,782466,Half-life,Half-life of minocycline in chronic renal failure (7 adult patients) was not prolonged (15--20 h).,[Activity in vitro and pharmacokinetics of minocycline (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/782466/),h,15--20,32228,DB01017,Minocycline
,20462741,minimum inhibitory concentrations/minimum bactericidal concentrations (MICs/MBCs),"One meticillin-resistant vancomycin-heteroresistant Staphylococcus aureus, one Enterococcus faecium and one extended-spectrum beta-lactamase-producing Escherichia coli with equal tigecycline minimum inhibitory concentrations/minimum bactericidal concentrations (MICs/MBCs) (0.12/0.25 microg/mL) were used.",Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20462741/),[μg] / [ml],0.12,32641,DB01017,Minocycline
,20462741,minimum inhibitory concentrations/minimum bactericidal concentrations (MICs/MBCs),"One meticillin-resistant vancomycin-heteroresistant Staphylococcus aureus, one Enterococcus faecium and one extended-spectrum beta-lactamase-producing Escherichia coli with equal tigecycline minimum inhibitory concentrations/minimum bactericidal concentrations (MICs/MBCs) (0.12/0.25 microg/mL) were used.",Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20462741/),[μg] / [ml],0.25,32642,DB01017,Minocycline
,20462741,area under the concentration-time curve (AUC)/MIC,"With standard inocula [ca. 1 x 10(6)colony-forming units (CFU)/mL], linear increases in area under the concentration-time curve (AUC)/MIC (25.6 for 50mg, 53.76 for 100mg and 79.52 for 150 mg) produced linear increases in activity against Gram-positive organisms (mean ABBCs of 120.60, 143.20 and 195.80 log CFU x h/mL for S. aureus and of 95.75, 172.55 and 216.90 log CFUxh/mL for E. faecium, respectively), with the activity of the 150 mg regimen being significantly higher (P<0.01) than that of the other two regimens.",Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20462741/),,25.6,32643,DB01017,Minocycline
,20462741,area under the concentration-time curve (AUC)/MIC,"With standard inocula [ca. 1 x 10(6)colony-forming units (CFU)/mL], linear increases in area under the concentration-time curve (AUC)/MIC (25.6 for 50mg, 53.76 for 100mg and 79.52 for 150 mg) produced linear increases in activity against Gram-positive organisms (mean ABBCs of 120.60, 143.20 and 195.80 log CFU x h/mL for S. aureus and of 95.75, 172.55 and 216.90 log CFUxh/mL for E. faecium, respectively), with the activity of the 150 mg regimen being significantly higher (P<0.01) than that of the other two regimens.",Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20462741/),,53.76,32644,DB01017,Minocycline
,20462741,area under the concentration-time curve (AUC)/MIC,"With standard inocula [ca. 1 x 10(6)colony-forming units (CFU)/mL], linear increases in area under the concentration-time curve (AUC)/MIC (25.6 for 50mg, 53.76 for 100mg and 79.52 for 150 mg) produced linear increases in activity against Gram-positive organisms (mean ABBCs of 120.60, 143.20 and 195.80 log CFU x h/mL for S. aureus and of 95.75, 172.55 and 216.90 log CFUxh/mL for E. faecium, respectively), with the activity of the 150 mg regimen being significantly higher (P<0.01) than that of the other two regimens.",Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20462741/),,79.52,32645,DB01017,Minocycline
,20462741,ABBCs,"With standard inocula [ca. 1 x 10(6)colony-forming units (CFU)/mL], linear increases in area under the concentration-time curve (AUC)/MIC (25.6 for 50mg, 53.76 for 100mg and 79.52 for 150 mg) produced linear increases in activity against Gram-positive organisms (mean ABBCs of 120.60, 143.20 and 195.80 log CFU x h/mL for S. aureus and of 95.75, 172.55 and 216.90 log CFUxh/mL for E. faecium, respectively), with the activity of the 150 mg regimen being significantly higher (P<0.01) than that of the other two regimens.",Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20462741/),[cfu·h·log] / [ml],120.60,32646,DB01017,Minocycline
,20462741,ABBCs,"With standard inocula [ca. 1 x 10(6)colony-forming units (CFU)/mL], linear increases in area under the concentration-time curve (AUC)/MIC (25.6 for 50mg, 53.76 for 100mg and 79.52 for 150 mg) produced linear increases in activity against Gram-positive organisms (mean ABBCs of 120.60, 143.20 and 195.80 log CFU x h/mL for S. aureus and of 95.75, 172.55 and 216.90 log CFUxh/mL for E. faecium, respectively), with the activity of the 150 mg regimen being significantly higher (P<0.01) than that of the other two regimens.",Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20462741/),[cfu·h·log] / [ml],143.20,32647,DB01017,Minocycline
,20462741,ABBCs,"With standard inocula [ca. 1 x 10(6)colony-forming units (CFU)/mL], linear increases in area under the concentration-time curve (AUC)/MIC (25.6 for 50mg, 53.76 for 100mg and 79.52 for 150 mg) produced linear increases in activity against Gram-positive organisms (mean ABBCs of 120.60, 143.20 and 195.80 log CFU x h/mL for S. aureus and of 95.75, 172.55 and 216.90 log CFUxh/mL for E. faecium, respectively), with the activity of the 150 mg regimen being significantly higher (P<0.01) than that of the other two regimens.",Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20462741/),[cfu·h·log] / [ml],195.80,32648,DB01017,Minocycline
,20462741,ABBCs,"With standard inocula [ca. 1 x 10(6)colony-forming units (CFU)/mL], linear increases in area under the concentration-time curve (AUC)/MIC (25.6 for 50mg, 53.76 for 100mg and 79.52 for 150 mg) produced linear increases in activity against Gram-positive organisms (mean ABBCs of 120.60, 143.20 and 195.80 log CFU x h/mL for S. aureus and of 95.75, 172.55 and 216.90 log CFUxh/mL for E. faecium, respectively), with the activity of the 150 mg regimen being significantly higher (P<0.01) than that of the other two regimens.",Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20462741/),[cfu·h·log] / [ml],95.75,32649,DB01017,Minocycline
,20462741,ABBCs,"With standard inocula [ca. 1 x 10(6)colony-forming units (CFU)/mL], linear increases in area under the concentration-time curve (AUC)/MIC (25.6 for 50mg, 53.76 for 100mg and 79.52 for 150 mg) produced linear increases in activity against Gram-positive organisms (mean ABBCs of 120.60, 143.20 and 195.80 log CFU x h/mL for S. aureus and of 95.75, 172.55 and 216.90 log CFUxh/mL for E. faecium, respectively), with the activity of the 150 mg regimen being significantly higher (P<0.01) than that of the other two regimens.",Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20462741/),[cfu·h·log] / [ml],172.55,32650,DB01017,Minocycline
,20462741,ABBCs,"With standard inocula [ca. 1 x 10(6)colony-forming units (CFU)/mL], linear increases in area under the concentration-time curve (AUC)/MIC (25.6 for 50mg, 53.76 for 100mg and 79.52 for 150 mg) produced linear increases in activity against Gram-positive organisms (mean ABBCs of 120.60, 143.20 and 195.80 log CFU x h/mL for S. aureus and of 95.75, 172.55 and 216.90 log CFUxh/mL for E. faecium, respectively), with the activity of the 150 mg regimen being significantly higher (P<0.01) than that of the other two regimens.",Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20462741/),[cfu·h·log] / [ml],216.90,32651,DB01017,Minocycline
,20462741,ABBCs,"Against E. coli, the highest dosing regimen was required to obtain significant antibacterial activity compared with control (mean ABBCs of 145.75 log CFU x h/mL with standard inocula and 63.33 log CFU x h/mL with high inocula).",Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20462741/),[cfu·h·log] / [ml],145.75,32652,DB01017,Minocycline
,20462741,ABBCs,"Against E. coli, the highest dosing regimen was required to obtain significant antibacterial activity compared with control (mean ABBCs of 145.75 log CFU x h/mL with standard inocula and 63.33 log CFU x h/mL with high inocula).",Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20462741/),[cfu·h·log] / [ml],63.33,32653,DB01017,Minocycline
,32690646,area under the concentration-time curve from 0 to 24 h (AUC0-24)/MIC,"As monotherapy, tedizolid at an observed area under the concentration-time curve from 0 to 24 h (AUC0-24)/MIC of 5.85 and minocycline at an AUC0-24/MIC of 5.77 failed to kill the bacteria below day 0 (stasis), clarithromycin at an AUC0-24/MIC of 2.4 held the bacterial burden at stasis, but rifapentine at an AUC0-24/MIC of 140 killed 2 log10 CFU/ml below stasis.","Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32690646/),,5.85,37069,DB01017,Minocycline
,32690646,AUC0-24/MIC,"As monotherapy, tedizolid at an observed area under the concentration-time curve from 0 to 24 h (AUC0-24)/MIC of 5.85 and minocycline at an AUC0-24/MIC of 5.77 failed to kill the bacteria below day 0 (stasis), clarithromycin at an AUC0-24/MIC of 2.4 held the bacterial burden at stasis, but rifapentine at an AUC0-24/MIC of 140 killed 2 log10 CFU/ml below stasis.","Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32690646/),,5.77,37070,DB01017,Minocycline
,32690646,AUC0-24/MIC,"As monotherapy, tedizolid at an observed area under the concentration-time curve from 0 to 24 h (AUC0-24)/MIC of 5.85 and minocycline at an AUC0-24/MIC of 5.77 failed to kill the bacteria below day 0 (stasis), clarithromycin at an AUC0-24/MIC of 2.4 held the bacterial burden at stasis, but rifapentine at an AUC0-24/MIC of 140 killed 2 log10 CFU/ml below stasis.","Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32690646/),,2.4,37071,DB01017,Minocycline
,32690646,AUC0-24/MIC,"As monotherapy, tedizolid at an observed area under the concentration-time curve from 0 to 24 h (AUC0-24)/MIC of 5.85 and minocycline at an AUC0-24/MIC of 5.77 failed to kill the bacteria below day 0 (stasis), clarithromycin at an AUC0-24/MIC of 2.4 held the bacterial burden at stasis, but rifapentine at an AUC0-24/MIC of 140 killed 2 log10 CFU/ml below stasis.","Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32690646/),,140,37072,DB01017,Minocycline
,32690646,combination kill slope,"The rifapentine-tedizolid-minocycline combination kill slope was -0.119 ± 0.031 CFU/ml/day, superior to that of the ATS regimen and comparable to that of the BTS regimen.","Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32690646/),[cfu] / [d·ml],-,37073,DB01017,Minocycline
,32690646,combination kill slope,"The rifapentine-tedizolid-minocycline combination kill slope was -0.119 ± 0.031 CFU/ml/day, superior to that of the ATS regimen and comparable to that of the BTS regimen.","Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32690646/),[cfu] / [d·ml],0.119,37074,DB01017,Minocycline
,19732498,cerebral AUC0-infinity /plasmatic AUC0-infinity ratio,"At the dose of 10 mg/kg, the cerebral AUC0-infinity /plasmatic AUC0-infinity ratio was 4.6 in mdr1a (-/-) mice and 2.4 in mdr1a (+/+) mice.",Brain and plasma riluzole pharmacokinetics: effect of minocycline combination. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19732498/),,4.6,37711,DB01017,Minocycline
,19732498,cerebral AUC0-infinity /plasmatic AUC0-infinity ratio,"At the dose of 10 mg/kg, the cerebral AUC0-infinity /plasmatic AUC0-infinity ratio was 4.6 in mdr1a (-/-) mice and 2.4 in mdr1a (+/+) mice.",Brain and plasma riluzole pharmacokinetics: effect of minocycline combination. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19732498/),,2.4,37712,DB01017,Minocycline
,24659422,recovery,The mean recovery ranged from 94.3 to 105.6% and the matrix effect from 92.1 to 97.6%.,Quantitative analysis and pharmacokinetics study of tigecycline in human serum using a validated sensitive liquid chromatography with tandem mass spectrometry method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24659422/),%,94.3 to 105.6,42026,DB01017,Minocycline
,24659422,matrix effect,The mean recovery ranged from 94.3 to 105.6% and the matrix effect from 92.1 to 97.6%.,Quantitative analysis and pharmacokinetics study of tigecycline in human serum using a validated sensitive liquid chromatography with tandem mass spectrometry method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24659422/),%,92.1 to 97.6,42027,DB01017,Minocycline
,29316830,susceptibility rate,"The susceptibility rate of tigecycline and minocycline were 79.9% and 41.5%, respectively.",Use of Monte Carlo simulation to evaluate the efficacy of tigecycline and minocycline for the treatment of pneumonia due to carbapenemase-producing Klebsiella pneumoniae. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29316830/),%,79.9,42226,DB01017,Minocycline
,29316830,susceptibility rate,"The susceptibility rate of tigecycline and minocycline were 79.9% and 41.5%, respectively.",Use of Monte Carlo simulation to evaluate the efficacy of tigecycline and minocycline for the treatment of pneumonia due to carbapenemase-producing Klebsiella pneumoniae. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29316830/),%,41.5,42227,DB01017,Minocycline
≤,29316830,MICs,"At recommended doses, an optimal PTA of 90% was obtained for treating HAP caused by CP-KP with MICs of tigecycline ≤0.5 mg/L or minocycline ≤4 mg/L.",Use of Monte Carlo simulation to evaluate the efficacy of tigecycline and minocycline for the treatment of pneumonia due to carbapenemase-producing Klebsiella pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29316830/),[mg] / [l],0.5,42228,DB01017,Minocycline
≤,29316830,MICs,"At recommended doses, an optimal PTA of 90% was obtained for treating HAP caused by CP-KP with MICs of tigecycline ≤0.5 mg/L or minocycline ≤4 mg/L.",Use of Monte Carlo simulation to evaluate the efficacy of tigecycline and minocycline for the treatment of pneumonia due to carbapenemase-producing Klebsiella pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29316830/),[mg] / [l],4,42229,DB01017,Minocycline
≤,29316830,MICs,minocycline (200 mg q12h) might be a potential alternative of tigecycline to against strains with MICs ≤ 8 mg/L.,Use of Monte Carlo simulation to evaluate the efficacy of tigecycline and minocycline for the treatment of pneumonia due to carbapenemase-producing Klebsiella pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29316830/),[mg] / [l],8,42230,DB01017,Minocycline
,8031039,MICs,"The MICs of sparfloxacin, erythromycin, levofloxacin, ofloxacin, and minocycline for 90% of the 43 M. pneumoniae strains tested were 0.063, 0.016, 0.5, 1, and 0.5 microgram/ml, respectively.",In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031039/),[μg] / [ml],0.063,43941,DB01017,Minocycline
,8031039,MICs,"The MICs of sparfloxacin, erythromycin, levofloxacin, ofloxacin, and minocycline for 90% of the 43 M. pneumoniae strains tested were 0.063, 0.016, 0.5, 1, and 0.5 microgram/ml, respectively.",In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031039/),[μg] / [ml],0.016,43942,DB01017,Minocycline
,8031039,MICs,"The MICs of sparfloxacin, erythromycin, levofloxacin, ofloxacin, and minocycline for 90% of the 43 M. pneumoniae strains tested were 0.063, 0.016, 0.5, 1, and 0.5 microgram/ml, respectively.",In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031039/),[μg] / [ml],0.5,43943,DB01017,Minocycline
,8031039,MICs,"The MICs of sparfloxacin, erythromycin, levofloxacin, ofloxacin, and minocycline for 90% of the 43 M. pneumoniae strains tested were 0.063, 0.016, 0.5, 1, and 0.5 microgram/ml, respectively.",In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031039/),[μg] / [ml],1,43944,DB01017,Minocycline
≥,33283892,AUC0-12h × V/MIC ratio,Classification and regression tree analyses indicated that the combination of APACHEII score < 24 and AUC0-12h × V/MIC ratio ≥ 100 was associated with clinical success.,Population pharmacokinetics and exposure-response analysis of tigecycline in patients with hospital-acquired pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33283892/),,100,49287,DB01017,Minocycline
,21950341,peak concentration,"At steady state, the mean ± s.d. peak concentration of minocycline in the plasma was 0.67 ± 0.26 µg/ml and the mean half-life was 11.48 ± 3.23 h.",Pharmacokinetics and distribution of minocycline in mature horses after oral administration of multiple doses and comparison with minimum inhibitory concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950341/),[μg] / [ml],0.67,50696,DB01017,Minocycline
,21950341,half-life,"At steady state, the mean ± s.d. peak concentration of minocycline in the plasma was 0.67 ± 0.26 µg/ml and the mean half-life was 11.48 ± 3.23 h.",Pharmacokinetics and distribution of minocycline in mature horses after oral administration of multiple doses and comparison with minimum inhibitory concentrations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950341/),h,11.48,50697,DB01017,Minocycline
,21950341,trough synovial fluid minocycline concentration,The highest trough synovial fluid minocycline concentration was 0.33 ± 0.12 µg/ml.,Pharmacokinetics and distribution of minocycline in mature horses after oral administration of multiple doses and comparison with minimum inhibitory concentrations. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950341/),[μg] / [ml],0.33,50698,DB01017,Minocycline
,21950341,AH concentration,The AH concentration of minocycline was 0.09 ± 0.03 µg/ml in normal eyes and 0.11 ± 0.04 µg/ml in blood aqueous barrier-disrupted eyes.,Pharmacokinetics and distribution of minocycline in mature horses after oral administration of multiple doses and comparison with minimum inhibitory concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950341/),[μg] / [ml],0.09,50699,DB01017,Minocycline
,21950341,AH concentration,The AH concentration of minocycline was 0.09 ± 0.03 µg/ml in normal eyes and 0.11 ± 0.04 µg/ml in blood aqueous barrier-disrupted eyes.,Pharmacokinetics and distribution of minocycline in mature horses after oral administration of multiple doses and comparison with minimum inhibitory concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950341/),[μg] / [ml],0.11,50700,DB01017,Minocycline
,21950341,CSF concentration,The mean CSF concentration of minocycline was 0.38 ± 0.09 µg/ml.,Pharmacokinetics and distribution of minocycline in mature horses after oral administration of multiple doses and comparison with minimum inhibitory concentrations. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950341/),[μg] / [ml],0.38,50701,DB01017,Minocycline
≤,21950341,MIC,This study supports the use of orally administered minocycline at a dose of 4 mg/kg bwt every 12 h for the treatment of nonocular infections caused by susceptible (MIC ≤ 0.25 µg/ml) organisms in horses.,Pharmacokinetics and distribution of minocycline in mature horses after oral administration of multiple doses and comparison with minimum inhibitory concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950341/),[μg] / [ml],0.25,50702,DB01017,Minocycline
,29036256,Cmax,"Following topical application of a 4-g maximal-use dose of minocycline foam 4% for 21 days, plasma minocycline concentration was very low, with geometric mean Cmax values ranging from 1.1 ng/mL to 1.5 ng/mL.",Pharmacokinetic Comparison of Once-Daily Topical Minocycline Foam 4% vs Oral Minocycline for Moderate-to-Severe Acne. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29036256/),[ng] / [ml],1.1,51209,DB01017,Minocycline
,29036256,Cmax,"Following topical application of a 4-g maximal-use dose of minocycline foam 4% for 21 days, plasma minocycline concentration was very low, with geometric mean Cmax values ranging from 1.1 ng/mL to 1.5 ng/mL.",Pharmacokinetic Comparison of Once-Daily Topical Minocycline Foam 4% vs Oral Minocycline for Moderate-to-Severe Acne. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29036256/),[ng] / [ml],1.5,51210,DB01017,Minocycline
,19114676,half-life,"Tigecycline pharmacokinetics were best described by a two-compartment model, with a mean half-life of 9.9 h.",Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19114676/),h,9.9,55896,DB01017,Minocycline
,19114676,MICs,"MICs were 0.25 microg/ml for all isolates, except for HA-MRSA 56 (MIC, 0.5 microg/ml) and CA-MRSA 156 (MIC, 0.125 microg/ml).",Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19114676/),[μg] / [ml],0.25,55897,DB01017,Minocycline
,19114676,MIC,"MICs were 0.25 microg/ml for all isolates, except for HA-MRSA 56 (MIC, 0.5 microg/ml) and CA-MRSA 156 (MIC, 0.125 microg/ml).",Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19114676/),[μg] / [ml],0.5,55898,DB01017,Minocycline
,19114676,MIC,"MICs were 0.25 microg/ml for all isolates, except for HA-MRSA 56 (MIC, 0.5 microg/ml) and CA-MRSA 156 (MIC, 0.125 microg/ml).",Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19114676/),[μg] / [ml],0.125,55899,DB01017,Minocycline
,19114676,effective exposure index,"Values for the mean effective exposure index at 80% (EI(80)) and 50% (EI(50)) for fAUC/MIC were 5.4 microg/ml (range, 2.8 to 13 microg/ml) and 2.6 microg/ml (range, 0.6 to 5.1 microg/ml), respectively.",Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19114676/),[μg] / [ml],5.4,55900,DB01017,Minocycline
,19114676,fAUC/MIC,"Values for the mean effective exposure index at 80% (EI(80)) and 50% (EI(50)) for fAUC/MIC were 5.4 microg/ml (range, 2.8 to 13 microg/ml) and 2.6 microg/ml (range, 0.6 to 5.1 microg/ml), respectively.",Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19114676/),[μg] / [ml],5.4,55901,DB01017,Minocycline
,19114676,fAUC/MIC,"Values for the mean effective exposure index at 80% (EI(80)) and 50% (EI(50)) for fAUC/MIC were 5.4 microg/ml (range, 2.8 to 13 microg/ml) and 2.6 microg/ml (range, 0.6 to 5.1 microg/ml), respectively.",Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19114676/),[μg] / [ml],2.6,55902,DB01017,Minocycline
,19114676,fAUC/MIC,Experiments with nonneutropenic mice infected with CA-MRSA 156 resulted in maximum kill at all fAUC/MIC exposures tested (1.8 to 8.8 microg/ml).,Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19114676/),[μg] / [ml],1.8 to 8.8,55903,DB01017,Minocycline
,3083734,clearance,"Pharmacokinetic values obtained from the sheep with normal serum protein were 5.94 +/- 1.78 ml/kg/min for clearance, 1.32 +/- 0.16 L/kg for the steady-state volume of distribution, and 3.89 +/- 0.80 hours for mean residence time.",Pharmacokinetics of minocycline hydrochloride in clinically normal and hypoproteinemic sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3083734/),[ml] / [kg·min],5.94,61199,DB01017,Minocycline
,3083734,steady-state volume of distribution,"Pharmacokinetic values obtained from the sheep with normal serum protein were 5.94 +/- 1.78 ml/kg/min for clearance, 1.32 +/- 0.16 L/kg for the steady-state volume of distribution, and 3.89 +/- 0.80 hours for mean residence time.",Pharmacokinetics of minocycline hydrochloride in clinically normal and hypoproteinemic sheep. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3083734/),[l] / [kg],1.32,61200,DB01017,Minocycline
,3083734,mean residence time,"Pharmacokinetic values obtained from the sheep with normal serum protein were 5.94 +/- 1.78 ml/kg/min for clearance, 1.32 +/- 0.16 L/kg for the steady-state volume of distribution, and 3.89 +/- 0.80 hours for mean residence time.",Pharmacokinetics of minocycline hydrochloride in clinically normal and hypoproteinemic sheep. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3083734/),h,3.89,61201,DB01017,Minocycline
,3083734,effective half-life,"The effective half-life, reported as the harmonic mean, increased from 2.57 hours in sheep before blood collection to 2.91 hours in sheep when they were hypoproteinemic.",Pharmacokinetics of minocycline hydrochloride in clinically normal and hypoproteinemic sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3083734/),h,2.57,61202,DB01017,Minocycline
,3083734,effective half-life,"The effective half-life, reported as the harmonic mean, increased from 2.57 hours in sheep before blood collection to 2.91 hours in sheep when they were hypoproteinemic.",Pharmacokinetics of minocycline hydrochloride in clinically normal and hypoproteinemic sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3083734/),h,2.91,61203,DB01017,Minocycline
> or =,19643776,MIC,"Nine E. coli isolates were studied, including three ESBL-producing isolates, three AmpC-producing isolates and three isolates demonstrating CRS (ertapenem MIC > or = 0.12 mg/L).","Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19643776/),[mg] / [l],0.12,64558,DB01017,Minocycline
,19643776,fC(max),"The pharmacodynamic model was inoculated with organisms at 1 x 10(6) cfu/mL and tigecycline dosed once every 24 h to simulate the fC(max) (free peak serum concentration) and t(1/2) (serum half-life) obtained after standard dosing of 100 mg intravenously every 24 h (fC(max), 0.15 mg/L; t(1/2), 42 h).","Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19643776/),[mg] / [l],0.15,64559,DB01017,Minocycline
,19643776,t(1/2),"The pharmacodynamic model was inoculated with organisms at 1 x 10(6) cfu/mL and tigecycline dosed once every 24 h to simulate the fC(max) (free peak serum concentration) and t(1/2) (serum half-life) obtained after standard dosing of 100 mg intravenously every 24 h (fC(max), 0.15 mg/L; t(1/2), 42 h).","Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19643776/),h,42,64560,DB01017,Minocycline
,19643776,fAUC(24)/MIC,"For isolates with a tigecycline fAUC(24)/MIC of 2.0 (tigecycline MIC = 0.5 mg/L), tigecycline demonstrated bacteriostatic activity with < 1 log(10) reduction in bacterial growth compared with the initial inoculum at 12, 24 and 48 h.","Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19643776/),,2.0,64561,DB01017,Minocycline
,19643776,MIC,"For isolates with a tigecycline fAUC(24)/MIC of 2.0 (tigecycline MIC = 0.5 mg/L), tigecycline demonstrated bacteriostatic activity with < 1 log(10) reduction in bacterial growth compared with the initial inoculum at 12, 24 and 48 h.","Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19643776/),[mg] / [l],0.5,64562,DB01017,Minocycline
,19643776,fAUC(24)/MIC,"Against the two isolates for which the tigecycline fAUC(24)/MIC was 4.0 (tigecycline MIC = 0.25 mg/L), tigecycline demonstrated bacteriostatic activity with approximately 1.5 log(10) reduction in bacterial growth compared with the initial inoculum at 12, 24 and 48 h.","Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19643776/),,4.0,64563,DB01017,Minocycline
,19643776,MIC,"Against the two isolates for which the tigecycline fAUC(24)/MIC was 4.0 (tigecycline MIC = 0.25 mg/L), tigecycline demonstrated bacteriostatic activity with approximately 1.5 log(10) reduction in bacterial growth compared with the initial inoculum at 12, 24 and 48 h.","Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19643776/),[mg] / [l],0.25,64564,DB01017,Minocycline
,19643776,fAUC(24)/MIC,"Against the two isolates for which the tigecycline fAUC(24)/MIC was 8.0 (tigecycline MIC = 0.12 mg/L), tigecycline demonstrated bacteriostatic activity with approximately 2.0 log(10) reduction in bacterial growth compared with the initial inoculum at 12, 24 and 48 h.","Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19643776/),,8.0,64565,DB01017,Minocycline
,19643776,MIC,"Against the two isolates for which the tigecycline fAUC(24)/MIC was 8.0 (tigecycline MIC = 0.12 mg/L), tigecycline demonstrated bacteriostatic activity with approximately 2.0 log(10) reduction in bacterial growth compared with the initial inoculum at 12, 24 and 48 h.","Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19643776/),[mg] / [l],0.12,64566,DB01017,Minocycline
,30844627,extraction recoveries,Mean extraction recoveries ranged between 64.3% and 84.6% for MC and 64.3% for the IS.,"Development, validation and application of a novel HPLC-MS/MS method for the measurement of minocycline in human plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30844627/),%,64.3,66637,DB01017,Minocycline
,30844627,extraction recoveries,Mean extraction recoveries ranged between 64.3% and 84.6% for MC and 64.3% for the IS.,"Development, validation and application of a novel HPLC-MS/MS method for the measurement of minocycline in human plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30844627/),%,84.6,66638,DB01017,Minocycline
,27682322,elimination half-life,"After i.v. administration to foals, minocycline had a mean (±SD) elimination half-life of 8.5 ± 2.1 h, a systemic clearance of 113.3 ± 26.1 mL/h/kg, and an apparent volume of distribution of 1.24 ± 0.19 L/kg.",Comparative pharmacokinetics of minocycline in foals and adult horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27682322/),h,8.5,67217,DB01017,Minocycline
,27682322,systemic clearance,"After i.v. administration to foals, minocycline had a mean (±SD) elimination half-life of 8.5 ± 2.1 h, a systemic clearance of 113.3 ± 26.1 mL/h/kg, and an apparent volume of distribution of 1.24 ± 0.19 L/kg.",Comparative pharmacokinetics of minocycline in foals and adult horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27682322/),[ml] / [h·kg],113.3,67218,DB01017,Minocycline
,27682322,apparent volume of distribution,"After i.v. administration to foals, minocycline had a mean (±SD) elimination half-life of 8.5 ± 2.1 h, a systemic clearance of 113.3 ± 26.1 mL/h/kg, and an apparent volume of distribution of 1.24 ± 0.19 L/kg.",Comparative pharmacokinetics of minocycline in foals and adult horses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27682322/),[l] / [kg],1.24,67219,DB01017,Minocycline
,27682322,Bioavailability,Bioavailability was significantly higher in foals (57.8 ± 19.3%) than in adult horses (32.0 ± 18.0%).,Comparative pharmacokinetics of minocycline in foals and adult horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27682322/),%,57.8,67220,DB01017,Minocycline
,27682322,Bioavailability,Bioavailability was significantly higher in foals (57.8 ± 19.3%) than in adult horses (32.0 ± 18.0%).,Comparative pharmacokinetics of minocycline in foals and adult horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27682322/),%,32.0,67221,DB01017,Minocycline
,24611544,maximum plasma concentration (CMAX ),"The maximum plasma concentration (CMAX ) and area under the curve (AUC) of minocycline were 1.15 μg/mL and 8.0 h* μg/mL, respectively.",Effect of sucralfate on oral minocycline absorption in healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24611544/),[μg] / [ml],1.15,75760,DB01017,Minocycline
,24611544,area under the curve (AUC),"The maximum plasma concentration (CMAX ) and area under the curve (AUC) of minocycline were 1.15 μg/mL and 8.0 h* μg/mL, respectively.",Effect of sucralfate on oral minocycline absorption in healthy dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24611544/),[h·μg] / [ml],8.0,75761,DB01017,Minocycline
,24611544,CMAX,"The CMAX and AUC were significantly lower (P < 0.05) in the MS group (CMAX = 0.33 μg/mL, AUC 3.0 h*μg/mL) compared with M or MS+2 (CMAX = 0.97 μg/mL, AUC 10.3 h*μg/mL).",Effect of sucralfate on oral minocycline absorption in healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24611544/),[μg] / [ml],0.33,75762,DB01017,Minocycline
,24611544,AUC,"The CMAX and AUC were significantly lower (P < 0.05) in the MS group (CMAX = 0.33 μg/mL, AUC 3.0 h*μg/mL) compared with M or MS+2 (CMAX = 0.97 μg/mL, AUC 10.3 h*μg/mL).",Effect of sucralfate on oral minocycline absorption in healthy dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24611544/),[h·μg] / [ml],3.0,75763,DB01017,Minocycline
,24611544,CMAX,"The CMAX and AUC were significantly lower (P < 0.05) in the MS group (CMAX = 0.33 μg/mL, AUC 3.0 h*μg/mL) compared with M or MS+2 (CMAX = 0.97 μg/mL, AUC 10.3 h*μg/mL).",Effect of sucralfate on oral minocycline absorption in healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24611544/),[μg] / [ml],0.97,75764,DB01017,Minocycline
,24611544,AUC,"The CMAX and AUC were significantly lower (P < 0.05) in the MS group (CMAX = 0.33 μg/mL, AUC 3.0 h*μg/mL) compared with M or MS+2 (CMAX = 0.97 μg/mL, AUC 10.3 h*μg/mL).",Effect of sucralfate on oral minocycline absorption in healthy dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24611544/),[h·μg] / [ml],10.3,75765,DB01017,Minocycline
,24611544,minimum inhibitory concentration (MIC),A dose of 7.5 mg/kg p.o. q12 h achieves the pharmacodynamic index for a bacterial minimum inhibitory concentration (MIC) of 0.25 μg/mL (AUC:MIC≥33.9).,Effect of sucralfate on oral minocycline absorption in healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24611544/),[μg] / [ml],0.25,75766,DB01017,Minocycline
≥,24611544,AUC:MIC,A dose of 7.5 mg/kg p.o. q12 h achieves the pharmacodynamic index for a bacterial minimum inhibitory concentration (MIC) of 0.25 μg/mL (AUC:MIC≥33.9).,Effect of sucralfate on oral minocycline absorption in healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24611544/),,33.9,75767,DB01017,Minocycline
,29076375,bioavailability,"RESULTS Mean bioavailability of minocycline was 48% (range, 35% to 75%).",Pulmonary disposition and pharmacokinetics of minocycline in adult horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29076375/),%,48,77056,DB01017,Minocycline
,29076375,maximum concentration (Cmax),"At steady state, mean ± SD maximum concentration (Cmax) of minocycline in plasma was 2.3 ± 1.3 μg/mL, and terminal half-life was 11.8 ± 0.5 hours.",Pulmonary disposition and pharmacokinetics of minocycline in adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29076375/),[μg] / [ml],2.3,77057,DB01017,Minocycline
,29076375,terminal half-life,"At steady state, mean ± SD maximum concentration (Cmax) of minocycline in plasma was 2.3 ± 1.3 μg/mL, and terminal half-life was 11.8 ± 0.5 hours.",Pulmonary disposition and pharmacokinetics of minocycline in adult horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29076375/),h,11.8,77058,DB01017,Minocycline
,29076375,time to Cmax (Tmax),"Median time to Cmax (Tmax) was 1.3 hours (interquartile range [IQR], 1.0 to 1.5 hours).",Pulmonary disposition and pharmacokinetics of minocycline in adult horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29076375/),h,1.3,77059,DB01017,Minocycline
,29076375,Cmax,"The Cmax and Tmax of minocycline in the PELF were 10.5 ± 12.8 μg/mL and 9.0 hours (IQR, 5.5 to 12.0 hours), respectively.",Pulmonary disposition and pharmacokinetics of minocycline in adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29076375/),[μg] / [ml],10.5,77060,DB01017,Minocycline
,29076375,Tmax,"The Cmax and Tmax of minocycline in the PELF were 10.5 ± 12.8 μg/mL and 9.0 hours (IQR, 5.5 to 12.0 hours), respectively.",Pulmonary disposition and pharmacokinetics of minocycline in adult horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29076375/),h,9.0,77061,DB01017,Minocycline
,29076375,Cmax,"The Cmax and Tmax for BAL cells were 0.24 ± 0.1 μg/mL and 6.0 hours (IQR, 0 to 6.0 hours), respectively.",Pulmonary disposition and pharmacokinetics of minocycline in adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29076375/),[μg] / [ml],0.24,77062,DB01017,Minocycline
,29076375,Tmax,"The Cmax and Tmax for BAL cells were 0.24 ± 0.1 μg/mL and 6.0 hours (IQR, 0 to 6.0 hours), respectively.",Pulmonary disposition and pharmacokinetics of minocycline in adult horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29076375/),h,6.0,77063,DB01017,Minocycline
,19139573,Drug,"Drug recovery from plasma, saliva and gingival fluid averaged 97.7%.","An HPTLC method for the determination of minocycline in human plasma, saliva, and gingival fluid after single step liquid extraction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19139573/),%,97.7,77364,DB01017,Minocycline
,19139573,recovery,"Drug recovery from plasma, saliva and gingival fluid averaged 97.7%.","An HPTLC method for the determination of minocycline in human plasma, saliva, and gingival fluid after single step liquid extraction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19139573/),%,97.7,77365,DB01017,Minocycline
,19139573,half-life of drug,"In all the three matrices, rapid degradation of drug occurred and the half-life of drug ranged from 9.9 to 16.1 h at 4 degrees C and from 6.3 to 11.5 h at 20 degrees C.","An HPTLC method for the determination of minocycline in human plasma, saliva, and gingival fluid after single step liquid extraction. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19139573/),h,9.9 to 16.1,77366,DB01017,Minocycline
,19139573,half-life of drug,"In all the three matrices, rapid degradation of drug occurred and the half-life of drug ranged from 9.9 to 16.1 h at 4 degrees C and from 6.3 to 11.5 h at 20 degrees C.","An HPTLC method for the determination of minocycline in human plasma, saliva, and gingival fluid after single step liquid extraction. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19139573/),h,6.3 to 11.5,77367,DB01017,Minocycline
,10718653,Recovery,Recovery from plasma or parotid saliva averaged 95%.,High-performance liquid chromatographic assay for minocycline in human plasma and parotid saliva. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10718653/),%,95,79302,DB01017,Minocycline
,10718653,percent recovery,"Frozen at -30 degrees C, this drug was stable for at least 2 months, the percent recovery averaged 90%.",High-performance liquid chromatographic assay for minocycline in human plasma and parotid saliva. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10718653/),%,90,79303,DB01017,Minocycline
,31970713,volume of distribution (Vd),"Omadacycline has a volume of distribution (Vd) ranging from 190 to 204 L, a terminal elimination half-life (t½) of 13.5-17.1 h, total clearance (CLT) of 8.8-10.6 L/h, and protein binding of 21.3% in healthy subjects.",Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31970713/),l,190 to 204,81440,DB01017,Minocycline
,31970713,terminal elimination half-life (t½),"Omadacycline has a volume of distribution (Vd) ranging from 190 to 204 L, a terminal elimination half-life (t½) of 13.5-17.1 h, total clearance (CLT) of 8.8-10.6 L/h, and protein binding of 21.3% in healthy subjects.",Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31970713/),h,13.5-17.1,81441,DB01017,Minocycline
,31970713,total clearance (CLT),"Omadacycline has a volume of distribution (Vd) ranging from 190 to 204 L, a terminal elimination half-life (t½) of 13.5-17.1 h, total clearance (CLT) of 8.8-10.6 L/h, and protein binding of 21.3% in healthy subjects.",Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31970713/),[l] / [h],8.8-10.6,81442,DB01017,Minocycline
,31970713,protein binding,"Omadacycline has a volume of distribution (Vd) ranging from 190 to 204 L, a terminal elimination half-life (t½) of 13.5-17.1 h, total clearance (CLT) of 8.8-10.6 L/h, and protein binding of 21.3% in healthy subjects.",Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31970713/),%,21.3,81443,DB01017,Minocycline
,31970713,Oral bioavailability,Oral bioavailability of omadacycline is estimated to be 34.5%.,Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31970713/),%,34.5,81444,DB01017,Minocycline
,31970713,maximum plasma concentration (Cmax),A single oral dose of 300 mg (bioequivalent to 100 mg IV) of omadacycline administered to fasted subjects achieved a maximum plasma concentration (Cmax) of 0.5-0.6 mg/L and an area under the plasma concentration-time curve from 0 to infinity (AUC0-∞) of 9.6-11.9 mg h/L.,Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31970713/),[mg] / [l],0.5-0.6,81445,DB01017,Minocycline
,31970713,area under the plasma concentration-time curve from 0 to infinity (AUC0-∞),A single oral dose of 300 mg (bioequivalent to 100 mg IV) of omadacycline administered to fasted subjects achieved a maximum plasma concentration (Cmax) of 0.5-0.6 mg/L and an area under the plasma concentration-time curve from 0 to infinity (AUC0-∞) of 9.6-11.9 mg h/L.,Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31970713/),[h·mg] / [l],9.6-11.9,81446,DB01017,Minocycline
≥,22143524,fAUC(0-24):MIC ratios,The odds of clinical success were 13.0 times higher for every 1-g/dl increase in albumin (P < 0.001) and 8.42 times higher for patients with fAUC(0-24):MIC ratios of ≥0.9 compared to patients with fAUC(0-24):MIC ratios of <0.9 (P = 0.008).,Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22143524/),,0.9,83894,DB01017,Minocycline
<,22143524,fAUC(0-24):MIC ratios,The odds of clinical success were 13.0 times higher for every 1-g/dl increase in albumin (P < 0.001) and 8.42 times higher for patients with fAUC(0-24):MIC ratios of ≥0.9 compared to patients with fAUC(0-24):MIC ratios of <0.9 (P = 0.008).,Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22143524/),,0.9,83895,DB01017,Minocycline
,22143524,MIC(50),"Among the remaining variables evaluated, the MIC had the greatest statistical significance, an observation which was not surprising given the differences in MIC distributions between VAP and non-VAP patients (MIC(50)and MIC(90) values of 0.5 and 0.25 mg/liter versus 16 and 1 mg/liter for VAP versus non-VAP patients, respectively; P = 0.006).",Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22143524/),[mg] / [l],0.5,83896,DB01017,Minocycline
,22143524,MIC(90),"Among the remaining variables evaluated, the MIC had the greatest statistical significance, an observation which was not surprising given the differences in MIC distributions between VAP and non-VAP patients (MIC(50)and MIC(90) values of 0.5 and 0.25 mg/liter versus 16 and 1 mg/liter for VAP versus non-VAP patients, respectively; P = 0.006).",Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22143524/),[mg] / [l],0.25,83897,DB01017,Minocycline
,22143524,MIC(90),"Among the remaining variables evaluated, the MIC had the greatest statistical significance, an observation which was not surprising given the differences in MIC distributions between VAP and non-VAP patients (MIC(50)and MIC(90) values of 0.5 and 0.25 mg/liter versus 16 and 1 mg/liter for VAP versus non-VAP patients, respectively; P = 0.006).",Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22143524/),[mg] / [l],16,83898,DB01017,Minocycline
,22143524,MIC(90),"Among the remaining variables evaluated, the MIC had the greatest statistical significance, an observation which was not surprising given the differences in MIC distributions between VAP and non-VAP patients (MIC(50)and MIC(90) values of 0.5 and 0.25 mg/liter versus 16 and 1 mg/liter for VAP versus non-VAP patients, respectively; P = 0.006).",Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22143524/),[mg] / [l],1,83899,DB01017,Minocycline
,25851119,Oral bioavailability,Oral bioavailability was approximately 62%.,Pharmacokinetics of minocycline in domestic cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25851119/),%,62,87182,DB01017,Minocycline
,25851119,Plasma protein binding,Plasma protein binding was 60% at 5 µg/ml and 46% at 1 μg/ml.,Pharmacokinetics of minocycline in domestic cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25851119/),%,60,87183,DB01017,Minocycline
,25851119,Plasma protein binding,Plasma protein binding was 60% at 5 µg/ml and 46% at 1 μg/ml.,Pharmacokinetics of minocycline in domestic cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25851119/),%,46,87184,DB01017,Minocycline
,25851119,elimination half-life (t(½)),"After IV administration, elimination half-life (t(½)), apparent volume of distribution at steady-state, and systemic clearance were 6.7 h (coefficient of variation [CV] 14.4%), 1.5 l/kg (CV 34.5%) and 2.9 ml/kg/min (CV 40.8%), respectively.",Pharmacokinetics of minocycline in domestic cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25851119/),h,6.7,87185,DB01017,Minocycline
,25851119,apparent volume of distribution at steady-state,"After IV administration, elimination half-life (t(½)), apparent volume of distribution at steady-state, and systemic clearance were 6.7 h (coefficient of variation [CV] 14.4%), 1.5 l/kg (CV 34.5%) and 2.9 ml/kg/min (CV 40.8%), respectively.",Pharmacokinetics of minocycline in domestic cats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25851119/),[l] / [kg],1.5,87186,DB01017,Minocycline
,25851119,systemic clearance,"After IV administration, elimination half-life (t(½)), apparent volume of distribution at steady-state, and systemic clearance were 6.7 h (coefficient of variation [CV] 14.4%), 1.5 l/kg (CV 34.5%) and 2.9 ml/kg/min (CV 40.8%), respectively.",Pharmacokinetics of minocycline in domestic cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25851119/),[ml] / [kg·min],2.9,87187,DB01017,Minocycline
,25851119,terminal t(½),"After oral administration the terminal t(½) and peak concentration (Cmax) were 6.3 h (CV 9%) and 4.77 µg/ml (CV 36%), respectively.",Pharmacokinetics of minocycline in domestic cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25851119/),h,6.3,87188,DB01017,Minocycline
,25851119,peak concentration (Cmax),"After oral administration the terminal t(½) and peak concentration (Cmax) were 6.3 h (CV 9%) and 4.77 µg/ml (CV 36%), respectively.",Pharmacokinetics of minocycline in domestic cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25851119/),[μg] / [ml],4.77,87189,DB01017,Minocycline
,25851119,minimum inhibitory concentration,"Because most bacteria will have a minimum inhibitory concentration of ⩽0.5 μg/ml, an oral dose of 8.8 mg/kg q24h would be adequate to meet pharmacokinetic-pharmacodynamic targets after adjusting for protein binding.",Pharmacokinetics of minocycline in domestic cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25851119/),[μg] / [ml],⩽0.5,87190,DB01017,Minocycline
,22249106,C(max),"The mean (SD) PK values were: C(max), 1899 (2954) ng/mL; T(max), 0.56 (0.18) hour; between-dose AUC, 2833 (1557) ng · h/mL; weight-normalized clearance, 0.503 (0.293) L/h/kg; and Vd(ss), 4.88 (4.84) L/kg.","Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22249106/),[ng] / [ml],1899,94328,DB01017,Minocycline
,22249106,T(max),"The mean (SD) PK values were: C(max), 1899 (2954) ng/mL; T(max), 0.56 (0.18) hour; between-dose AUC, 2833 (1557) ng · h/mL; weight-normalized clearance, 0.503 (0.293) L/h/kg; and Vd(ss), 4.88 (4.84) L/kg.","Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22249106/),h,0.56,94329,DB01017,Minocycline
,22249106,AUC,"The mean (SD) PK values were: C(max), 1899 (2954) ng/mL; T(max), 0.56 (0.18) hour; between-dose AUC, 2833 (1557) ng · h/mL; weight-normalized clearance, 0.503 (0.293) L/h/kg; and Vd(ss), 4.88 (4.84) L/kg.","Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22249106/),[h·ng] / [ml],2833,94330,DB01017,Minocycline
,22249106,weight-normalized clearance,"The mean (SD) PK values were: C(max), 1899 (2954) ng/mL; T(max), 0.56 (0.18) hour; between-dose AUC, 2833 (1557) ng · h/mL; weight-normalized clearance, 0.503 (0.293) L/h/kg; and Vd(ss), 4.88 (4.84) L/kg.","Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22249106/),[l] / [h·kg],0.503,94331,DB01017,Minocycline
,22249106,Vd(ss),"The mean (SD) PK values were: C(max), 1899 (2954) ng/mL; T(max), 0.56 (0.18) hour; between-dose AUC, 2833 (1557) ng · h/mL; weight-normalized clearance, 0.503 (0.293) L/h/kg; and Vd(ss), 4.88 (4.84) L/kg.","Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22249106/),[l] / [kg],4.88,94332,DB01017,Minocycline
,22249106,Overall clinical cure rates,"Overall clinical cure rates at test-of-cure were 94% (16/17), 76% (16/21), and 75% (15/20) in the 0.75-, 1-, and 1.25-mg/kg cohorts, respectively.","Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22249106/),%,94,94333,DB01017,Minocycline
,22249106,Overall clinical cure rates,"Overall clinical cure rates at test-of-cure were 94% (16/17), 76% (16/21), and 75% (15/20) in the 0.75-, 1-, and 1.25-mg/kg cohorts, respectively.","Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22249106/),%,76,94334,DB01017,Minocycline
,15885987,C(max),"The C(max) (mean+/-S.D.), AUC and half-life for serum were 0.72+/-0.24 microg/mL, 1.73+/-0.64 microg*h/mL and 15.0+/-1.10h; for lung epithelial lining fluid (ELF) the values were 0.37 microg/mL, 2.28 microg*h/mL and 39.1h; and for alveolar cells (AC) were 15.2 microg/mL, 134 microg*h/mL and 23.7h.",Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885987/),[μg] / [ml],0.72,94708,DB01017,Minocycline
,15885987,C(max),"The C(max) (mean+/-S.D.), AUC and half-life for serum were 0.72+/-0.24 microg/mL, 1.73+/-0.64 microg*h/mL and 15.0+/-1.10h; for lung epithelial lining fluid (ELF) the values were 0.37 microg/mL, 2.28 microg*h/mL and 39.1h; and for alveolar cells (AC) were 15.2 microg/mL, 134 microg*h/mL and 23.7h.",Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885987/),[μg] / [ml],0.37,94709,DB01017,Minocycline
,15885987,AUC,"The C(max) (mean+/-S.D.), AUC and half-life for serum were 0.72+/-0.24 microg/mL, 1.73+/-0.64 microg*h/mL and 15.0+/-1.10h; for lung epithelial lining fluid (ELF) the values were 0.37 microg/mL, 2.28 microg*h/mL and 39.1h; and for alveolar cells (AC) were 15.2 microg/mL, 134 microg*h/mL and 23.7h.",Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885987/),[h·μg] / [ml],1.73,94710,DB01017,Minocycline
,15885987,AUC,"The C(max) (mean+/-S.D.), AUC and half-life for serum were 0.72+/-0.24 microg/mL, 1.73+/-0.64 microg*h/mL and 15.0+/-1.10h; for lung epithelial lining fluid (ELF) the values were 0.37 microg/mL, 2.28 microg*h/mL and 39.1h; and for alveolar cells (AC) were 15.2 microg/mL, 134 microg*h/mL and 23.7h.",Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885987/),[μg] / [ml],0.37,94711,DB01017,Minocycline
,15885987,AUC,"The C(max) (mean+/-S.D.), AUC and half-life for serum were 0.72+/-0.24 microg/mL, 1.73+/-0.64 microg*h/mL and 15.0+/-1.10h; for lung epithelial lining fluid (ELF) the values were 0.37 microg/mL, 2.28 microg*h/mL and 39.1h; and for alveolar cells (AC) were 15.2 microg/mL, 134 microg*h/mL and 23.7h.",Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885987/),[h·μg] / [ml],2.28,94712,DB01017,Minocycline
,15885987,AUC,"The C(max) (mean+/-S.D.), AUC and half-life for serum were 0.72+/-0.24 microg/mL, 1.73+/-0.64 microg*h/mL and 15.0+/-1.10h; for lung epithelial lining fluid (ELF) the values were 0.37 microg/mL, 2.28 microg*h/mL and 39.1h; and for alveolar cells (AC) were 15.2 microg/mL, 134 microg*h/mL and 23.7h.",Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885987/),[μg] / [ml],15.2,94713,DB01017,Minocycline
,15885987,half-life,"The C(max) (mean+/-S.D.), AUC and half-life for serum were 0.72+/-0.24 microg/mL, 1.73+/-0.64 microg*h/mL and 15.0+/-1.10h; for lung epithelial lining fluid (ELF) the values were 0.37 microg/mL, 2.28 microg*h/mL and 39.1h; and for alveolar cells (AC) were 15.2 microg/mL, 134 microg*h/mL and 23.7h.",Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885987/),h,15.0,94714,DB01017,Minocycline
,15885987,half-life,"The C(max) (mean+/-S.D.), AUC and half-life for serum were 0.72+/-0.24 microg/mL, 1.73+/-0.64 microg*h/mL and 15.0+/-1.10h; for lung epithelial lining fluid (ELF) the values were 0.37 microg/mL, 2.28 microg*h/mL and 39.1h; and for alveolar cells (AC) were 15.2 microg/mL, 134 microg*h/mL and 23.7h.",Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885987/),h,39.1,94715,DB01017,Minocycline
,15885987,half-life,"The C(max) (mean+/-S.D.), AUC and half-life for serum were 0.72+/-0.24 microg/mL, 1.73+/-0.64 microg*h/mL and 15.0+/-1.10h; for lung epithelial lining fluid (ELF) the values were 0.37 microg/mL, 2.28 microg*h/mL and 39.1h; and for alveolar cells (AC) were 15.2 microg/mL, 134 microg*h/mL and 23.7h.",Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885987/),[μg] / [ml],15.2,94716,DB01017,Minocycline
,15885987,half-life,"The C(max) (mean+/-S.D.), AUC and half-life for serum were 0.72+/-0.24 microg/mL, 1.73+/-0.64 microg*h/mL and 15.0+/-1.10h; for lung epithelial lining fluid (ELF) the values were 0.37 microg/mL, 2.28 microg*h/mL and 39.1h; and for alveolar cells (AC) were 15.2 microg/mL, 134 microg*h/mL and 23.7h.",Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885987/),[h·μg] / [ml],134,94717,DB01017,Minocycline
,15885987,half-life,"The C(max) (mean+/-S.D.), AUC and half-life for serum were 0.72+/-0.24 microg/mL, 1.73+/-0.64 microg*h/mL and 15.0+/-1.10h; for lung epithelial lining fluid (ELF) the values were 0.37 microg/mL, 2.28 microg*h/mL and 39.1h; and for alveolar cells (AC) were 15.2 microg/mL, 134 microg*h/mL and 23.7h.",Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885987/),h,23.7,94718,DB01017,Minocycline
,15885987,C(max)/MIC(90) ratios,Tigecycline was concentrated in AC: C(max)/MIC(90) ratios ranged from 30.4 (H. influenzae) to 507 (S. pneumoniae); AUC/MIC(90) ratios ranged from 268 (H. influenzae) to 4467 (S. pneumoniae); and percentage dose interval above MIC(90) was 100% for the five respiratory pathogens.,Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885987/),,30.4,94719,DB01017,Minocycline
,15885987,C(max)/MIC(90) ratios,Tigecycline was concentrated in AC: C(max)/MIC(90) ratios ranged from 30.4 (H. influenzae) to 507 (S. pneumoniae); AUC/MIC(90) ratios ranged from 268 (H. influenzae) to 4467 (S. pneumoniae); and percentage dose interval above MIC(90) was 100% for the five respiratory pathogens.,Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885987/),,507,94720,DB01017,Minocycline
,15885987,AUC/MIC(90) ratios,Tigecycline was concentrated in AC: C(max)/MIC(90) ratios ranged from 30.4 (H. influenzae) to 507 (S. pneumoniae); AUC/MIC(90) ratios ranged from 268 (H. influenzae) to 4467 (S. pneumoniae); and percentage dose interval above MIC(90) was 100% for the five respiratory pathogens.,Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885987/),,268,94721,DB01017,Minocycline
,15885987,AUC/MIC(90) ratios,Tigecycline was concentrated in AC: C(max)/MIC(90) ratios ranged from 30.4 (H. influenzae) to 507 (S. pneumoniae); AUC/MIC(90) ratios ranged from 268 (H. influenzae) to 4467 (S. pneumoniae); and percentage dose interval above MIC(90) was 100% for the five respiratory pathogens.,Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885987/),,4467,94722,DB01017,Minocycline
<,11393692,run time,The method is fast (single liquid extraction and run time of <3 min) and sensitive (5 ng/ml) and it was employed in a bioequivalence study of two 100 mg tablet formulations in 24 healthy volunteers.,Determination of minocycline in human plasma by high-performance liquid chromatography coupled to tandem mass spectrometry: application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11393692/),min,3,95184,DB01017,Minocycline
,24243316,maximum concentration,"After 10 days of tigecycline 50 mg q12h, mean ± standard deviation pharmacokinetics in 8/10 subjects were: maximum concentration 1,118 ± 127 ng/mL, area under the concentration-time curve 0-12 hours 3,261 ± 937 ng h/mL, clearance 0.25 ± 0.05 L/h/kg, half-life 60.7 ± 23.4 hours, and volume of distribution 11.9 ± 2.3 L/kg.","Tigecycline pharmacokinetics, tolerability, safety, and effect on intestinal microflora in healthy Japanese male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24243316/),[ng] / [ml],"1,118",98451,DB01017,Minocycline
,24243316,area under the concentration-time curve 0-12 hours,"After 10 days of tigecycline 50 mg q12h, mean ± standard deviation pharmacokinetics in 8/10 subjects were: maximum concentration 1,118 ± 127 ng/mL, area under the concentration-time curve 0-12 hours 3,261 ± 937 ng h/mL, clearance 0.25 ± 0.05 L/h/kg, half-life 60.7 ± 23.4 hours, and volume of distribution 11.9 ± 2.3 L/kg.","Tigecycline pharmacokinetics, tolerability, safety, and effect on intestinal microflora in healthy Japanese male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24243316/),[h·ng] / [ml],"3,261",98452,DB01017,Minocycline
,24243316,clearance,"After 10 days of tigecycline 50 mg q12h, mean ± standard deviation pharmacokinetics in 8/10 subjects were: maximum concentration 1,118 ± 127 ng/mL, area under the concentration-time curve 0-12 hours 3,261 ± 937 ng h/mL, clearance 0.25 ± 0.05 L/h/kg, half-life 60.7 ± 23.4 hours, and volume of distribution 11.9 ± 2.3 L/kg.","Tigecycline pharmacokinetics, tolerability, safety, and effect on intestinal microflora in healthy Japanese male subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24243316/),[l] / [h·kg],0.25,98453,DB01017,Minocycline
,24243316,half-life,"After 10 days of tigecycline 50 mg q12h, mean ± standard deviation pharmacokinetics in 8/10 subjects were: maximum concentration 1,118 ± 127 ng/mL, area under the concentration-time curve 0-12 hours 3,261 ± 937 ng h/mL, clearance 0.25 ± 0.05 L/h/kg, half-life 60.7 ± 23.4 hours, and volume of distribution 11.9 ± 2.3 L/kg.","Tigecycline pharmacokinetics, tolerability, safety, and effect on intestinal microflora in healthy Japanese male subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24243316/),h,60.7,98454,DB01017,Minocycline
,24243316,volume of distribution,"After 10 days of tigecycline 50 mg q12h, mean ± standard deviation pharmacokinetics in 8/10 subjects were: maximum concentration 1,118 ± 127 ng/mL, area under the concentration-time curve 0-12 hours 3,261 ± 937 ng h/mL, clearance 0.25 ± 0.05 L/h/kg, half-life 60.7 ± 23.4 hours, and volume of distribution 11.9 ± 2.3 L/kg.","Tigecycline pharmacokinetics, tolerability, safety, and effect on intestinal microflora in healthy Japanese male subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24243316/),[l] / [kg],11.9,98455,DB01017,Minocycline
,23403419,maximum concentration of drug in serum (C(max)),"In the group given 50 mg of tigecycline, the pharmacokinetic parameters and means were as follows: maximum concentration of drug in serum (C(max)), 432 ng/ml; area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞), 2,366 ng · h/ml; clearance (CL), 21.1 liters/h; volume of distribution at steady state (V(ss)), 610 liters; and terminal half-life (t(1/2)), 22.1 h.",Tigecycline does not prolong corrected QT intervals in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23403419/),[ng] / [ml],432,101692,DB01017,Minocycline
,23403419,area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞),"In the group given 50 mg of tigecycline, the pharmacokinetic parameters and means were as follows: maximum concentration of drug in serum (C(max)), 432 ng/ml; area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞), 2,366 ng · h/ml; clearance (CL), 21.1 liters/h; volume of distribution at steady state (V(ss)), 610 liters; and terminal half-life (t(1/2)), 22.1 h.",Tigecycline does not prolong corrected QT intervals in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23403419/),[h·ng] / [ml],"2,366",101693,DB01017,Minocycline
,23403419,clearance (CL),"In the group given 50 mg of tigecycline, the pharmacokinetic parameters and means were as follows: maximum concentration of drug in serum (C(max)), 432 ng/ml; area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞), 2,366 ng · h/ml; clearance (CL), 21.1 liters/h; volume of distribution at steady state (V(ss)), 610 liters; and terminal half-life (t(1/2)), 22.1 h.",Tigecycline does not prolong corrected QT intervals in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23403419/),[l] / [h],21.1,101694,DB01017,Minocycline
,23403419,volume of distribution at steady state (V(ss)),"In the group given 50 mg of tigecycline, the pharmacokinetic parameters and means were as follows: maximum concentration of drug in serum (C(max)), 432 ng/ml; area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞), 2,366 ng · h/ml; clearance (CL), 21.1 liters/h; volume of distribution at steady state (V(ss)), 610 liters; and terminal half-life (t(1/2)), 22.1 h.",Tigecycline does not prolong corrected QT intervals in healthy subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23403419/),l,610,101695,DB01017,Minocycline
,23403419,terminal half-life (t(1/2)),"In the group given 50 mg of tigecycline, the pharmacokinetic parameters and means were as follows: maximum concentration of drug in serum (C(max)), 432 ng/ml; area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞), 2,366 ng · h/ml; clearance (CL), 21.1 liters/h; volume of distribution at steady state (V(ss)), 610 liters; and terminal half-life (t(1/2)), 22.1 h.",Tigecycline does not prolong corrected QT intervals in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23403419/),h,22.1,101696,DB01017,Minocycline
,28696233,area under the concentration-time curve (AUC) from time zero to 24 h postdosing (AUC0-24),"The value of the area under the concentration-time curve (AUC) from time zero to 24 h postdosing (AUC0-24) (based on mean concentrations) in ELF and the ratio of the ELF to total plasma omadacycline concentration based on AUC0-24 values were 17.23 mg · h/liter and 1.47, respectively.","Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28696233/),[h·mg] / [l],17.23,106328,DB01017,Minocycline
,28696233,area under the concentration-time curve (AUC) from time zero to 24 h postdosing (AUC0-24),"The value of the area under the concentration-time curve (AUC) from time zero to 24 h postdosing (AUC0-24) (based on mean concentrations) in ELF and the ratio of the ELF to total plasma omadacycline concentration based on AUC0-24 values were 17.23 mg · h/liter and 1.47, respectively.","Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28696233/),,1,106329,DB01017,Minocycline
,28696233,ratio,"The value of the area under the concentration-time curve (AUC) from time zero to 24 h postdosing (AUC0-24) (based on mean concentrations) in ELF and the ratio of the ELF to total plasma omadacycline concentration based on AUC0-24 values were 17.23 mg · h/liter and 1.47, respectively.","Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28696233/),[h·mg] / [l],17.23,106330,DB01017,Minocycline
,28696233,ratio,"The value of the area under the concentration-time curve (AUC) from time zero to 24 h postdosing (AUC0-24) (based on mean concentrations) in ELF and the ratio of the ELF to total plasma omadacycline concentration based on AUC0-24 values were 17.23 mg · h/liter and 1.47, respectively.","Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28696233/),,1,106331,DB01017,Minocycline
,28696233,AUC0-24,"The AUC0-24 value in AC was 302.46 mg · h/liter, and the ratio of the AC to total plasma omadacycline concentration was 25.8.","Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28696233/),[h·mg] / [l],302.46,106332,DB01017,Minocycline
,28696233,AUC from time zero to 12 h postdosing (AUC0-12),"In comparison, the values of the AUC from time zero to 12 h postdosing (AUC0-12) based on the mean concentrations of tigecycline in ELF and AC were 3.16 and 38.50 mg · h/liter, respectively.","Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28696233/),[h·mg] / [l],3.16,106333,DB01017,Minocycline
,28696233,AUC from time zero to 12 h postdosing (AUC0-12),"In comparison, the values of the AUC from time zero to 12 h postdosing (AUC0-12) based on the mean concentrations of tigecycline in ELF and AC were 3.16 and 38.50 mg · h/liter, respectively.","Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28696233/),[h·mg] / [l],38.50,106334,DB01017,Minocycline
,33066989,Cmax,The Cmax of MINO with 1.79 and 2.63 μg mL-1 was obtained at 2.96 and 1.41 h in TCF (tissue cage fluid) and plasma respectively.,Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),[μg] / [ml],1.79,107585,DB01017,Minocycline
,33066989,Cmax,The Cmax of MINO with 1.79 and 2.63 μg mL-1 was obtained at 2.96 and 1.41 h in TCF (tissue cage fluid) and plasma respectively.,Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),[μg] / [ml],2.63,107586,DB01017,Minocycline
,33066989,absorption half-lives (t1/2ka),"The absorption half-lives (t1/2ka) of MINO were calculated to be 0.71 h in TCF and 0.32 h in plasma, whereas the elimination half-lives (t1/2ke) were 10.46 h in TCF and 5.95 h in plasma.",Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),h,0.71,107587,DB01017,Minocycline
,33066989,absorption half-lives (t1/2ka),"The absorption half-lives (t1/2ka) of MINO were calculated to be 0.71 h in TCF and 0.32 h in plasma, whereas the elimination half-lives (t1/2ke) were 10.46 h in TCF and 5.95 h in plasma.",Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),h,0.32,107588,DB01017,Minocycline
,33066989,elimination half-lives (t1/2ke),"The absorption half-lives (t1/2ka) of MINO were calculated to be 0.71 h in TCF and 0.32 h in plasma, whereas the elimination half-lives (t1/2ke) were 10.46 h in TCF and 5.95 h in plasma.",Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),h,10.46,107589,DB01017,Minocycline
,33066989,elimination half-lives (t1/2ke),"The absorption half-lives (t1/2ka) of MINO were calculated to be 0.71 h in TCF and 0.32 h in plasma, whereas the elimination half-lives (t1/2ke) were 10.46 h in TCF and 5.95 h in plasma.",Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),h,5.95,107590,DB01017,Minocycline
,33066989,distribution volume (Vd/F),The distribution volume (Vd/F) of MINO was estimated to be 1.84 L kg-1 in TCF and 1.28 L kg-1 in plasma.,Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),[l] / [kg],1.84,107591,DB01017,Minocycline
,33066989,distribution volume (Vd/F),The distribution volume (Vd/F) of MINO was estimated to be 1.84 L kg-1 in TCF and 1.28 L kg-1 in plasma.,Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),[l] / [kg],1.28,107592,DB01017,Minocycline
,33066989,total clearance (CLb/F),The total clearance (CLb/F) of MINO was computed as 0.12 and 0.15 L/ (h·kg) in TCF and plasma respectively.,Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),[l] / [h·kg],0.12,107593,DB01017,Minocycline
,33066989,total clearance (CLb/F),The total clearance (CLb/F) of MINO was computed as 0.12 and 0.15 L/ (h·kg) in TCF and plasma respectively.,Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),[l] / [h·kg],0.15,107594,DB01017,Minocycline
,33066989,area under the concentration-time curve (AUC),"The area under the concentration-time curve (AUC) of MINO was 32.77 μg mL-1h in TCF and 25.27 μg mL-1h in plasma, respectively.",Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),[μg] / [ml],32.77,107595,DB01017,Minocycline
,33066989,area under the concentration-time curve (AUC),"The area under the concentration-time curve (AUC) of MINO was 32.77 μg mL-1h in TCF and 25.27 μg mL-1h in plasma, respectively.",Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),[μg] / [ml],25.27,107596,DB01017,Minocycline
,33066989,MIC,"The MIC and MBC of MINO against salmonella were 0.08 and 0.16 μg mL-1 for plasma, 0.04 and 0.08 μg mL-1 for TCF.",Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),[μg] / [ml],0.08,107597,DB01017,Minocycline
,33066989,MIC,"The MIC and MBC of MINO against salmonella were 0.08 and 0.16 μg mL-1 for plasma, 0.04 and 0.08 μg mL-1 for TCF.",Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),[μg] / [ml],0.04,107598,DB01017,Minocycline
,33066989,MBC,"The MIC and MBC of MINO against salmonella were 0.08 and 0.16 μg mL-1 for plasma, 0.04 and 0.08 μg mL-1 for TCF.",Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),[μg] / [ml],0.16,107599,DB01017,Minocycline
,33066989,MBC,"The MIC and MBC of MINO against salmonella were 0.08 and 0.16 μg mL-1 for plasma, 0.04 and 0.08 μg mL-1 for TCF.",Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),[μg] / [ml],0.08,107600,DB01017,Minocycline
,33066989,plasma,"The plasma Cmax/MIC and AUC/MIC values after IM administration were 32.88 ± 9.87 and 315.88 ± 42.65 h, respectively.",Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),h,32.88,107601,DB01017,Minocycline
,33066989,Cmax/MIC,"The plasma Cmax/MIC and AUC/MIC values after IM administration were 32.88 ± 9.87 and 315.88 ± 42.65 h, respectively.",Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),h,32.88,107602,DB01017,Minocycline
,33066989,AUC/MIC,"The plasma Cmax/MIC and AUC/MIC values after IM administration were 32.88 ± 9.87 and 315.88 ± 42.65 h, respectively.",Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),h,315.88,107603,DB01017,Minocycline
,33066989,Cmax/MIC,"The TCF Cmax/MIC and AUC/MIC values after IM administration were 44.75 ± 9.32 and 819.25 ± 65.23 h, respectively.",Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),h,44.75,107604,DB01017,Minocycline
,33066989,AUC/MIC,"The TCF Cmax/MIC and AUC/MIC values after IM administration were 44.75 ± 9.32 and 819.25 ± 65.23 h, respectively.",Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),h,819.25,107605,DB01017,Minocycline
>,33066989,T > MIC,The values of T > MIC were approximately >36 h in plasma and > 65 h in TCF.,Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),h,36,107606,DB01017,Minocycline
>,33066989,T > MIC,The values of T > MIC were approximately >36 h in plasma and > 65 h in TCF.,Pharmacokinetics and ex vivo pharmacodynamics of Minocycline against Salmonella abortus equi in donkey plasma and tissue cage fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33066989/),h,65,107607,DB01017,Minocycline
,19093704,Clinical cure rates,Clinical cure rates were 89.7% versus 86.3% in the clinically evaluable population and 81.0% versus 79.7% in the clinical modified intent-to-treat population.,Tigecycline: in community-acquired pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19093704/),%,89.7,114575,DB01017,Minocycline
,19093704,Clinical cure rates,Clinical cure rates were 89.7% versus 86.3% in the clinically evaluable population and 81.0% versus 79.7% in the clinical modified intent-to-treat population.,Tigecycline: in community-acquired pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19093704/),%,86.3,114576,DB01017,Minocycline
,19093704,Clinical cure rates,Clinical cure rates were 89.7% versus 86.3% in the clinically evaluable population and 81.0% versus 79.7% in the clinical modified intent-to-treat population.,Tigecycline: in community-acquired pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19093704/),%,81.0,114577,DB01017,Minocycline
,19093704,Clinical cure rates,Clinical cure rates were 89.7% versus 86.3% in the clinically evaluable population and 81.0% versus 79.7% in the clinical modified intent-to-treat population.,Tigecycline: in community-acquired pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19093704/),%,79.7,114578,DB01017,Minocycline
,24840325,elimination half-lives,"A large volume of distribution after oral administration, with plasma and ISF elimination half-lives of 4.1 and 7.4 h, respectively, demonstrated that the ISF serves as a drug reservoir for sustained tissue concentrations.",Minocycline pharmacokinetics and pharmacodynamics in dogs: dosage recommendations for treatment of meticillin-resistant Staphylococcus pseudintermedius infections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24840325/),h,4.1,114993,DB01017,Minocycline
,24840325,elimination half-lives,"A large volume of distribution after oral administration, with plasma and ISF elimination half-lives of 4.1 and 7.4 h, respectively, demonstrated that the ISF serves as a drug reservoir for sustained tissue concentrations.",Minocycline pharmacokinetics and pharmacodynamics in dogs: dosage recommendations for treatment of meticillin-resistant Staphylococcus pseudintermedius infections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24840325/),h,7.4,114994,DB01017,Minocycline
≤,24840325,minimal inhibitory concentrations,"Monte Carlo simulation, used to assess target attainment at different drug dosages, indicated that p.o. administration of 5 mg/kg twice daily is sufficient to inhibit S. pseudintermedius strains with minimal inhibitory concentrations ≤0.25 μg/mL.",Minocycline pharmacokinetics and pharmacodynamics in dogs: dosage recommendations for treatment of meticillin-resistant Staphylococcus pseudintermedius infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24840325/),[μg] / [ml],0.25,114995,DB01017,Minocycline
,26378888,extraction recovery,The mean extraction recovery in rat brain was 83.6%.,Development and validation of a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the quantification of tigecycline in rat brain tissues. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26378888/),%,83.6,117423,DB01017,Minocycline
> or =,20038623,ratio of the area under the concentration-time curve (AUC) to the MIC (AUC/MIC ratio),"A final multivariable logistic regression model demonstrated six factors based on 123 patients to be predictive of clinical success: a weight of <94 kg (P = 0.026), the absence of Pseudomonas aeruginosa in baseline cultures (P = 0.021), an APACHE II score of <13 (P = 0.029), non-Hispanic race (P = 0.005), complicated appendicitis or cholecystitis (P = 0.004), and a ratio of the area under the concentration-time curve (AUC) to the MIC (AUC/MIC ratio) of > or =3.1 (P = 0.003).",Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20038623/),,3.1,118165,DB01017,Minocycline
<,20038623,AUC/MIC ratio,This probability was lower (0.855) when the AUC/MIC ratio was < 3.1 and the remaining five factors were set to the favorable condition.,Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20038623/),,3.1,118166,DB01017,Minocycline
,19279050,half-life,Tigecycline displayed linear pharmacokinetics with a mean half-life of 11.3 +/- 1.4 h.,Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19279050/),h,11.3,121025,DB01017,Minocycline
,19279050,fAUC/MIC,"The mean 80%, 50% effective and stasis exposures (fAUC/MIC) were 17, 8 and 6, respectively.",Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19279050/),,17,121026,DB01017,Minocycline
,19279050,fAUC/MIC,"The mean 80%, 50% effective and stasis exposures (fAUC/MIC) were 17, 8 and 6, respectively.",Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19279050/),,8,121027,DB01017,Minocycline
,19279050,fAUC/MIC,"The mean 80%, 50% effective and stasis exposures (fAUC/MIC) were 17, 8 and 6, respectively.",Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19279050/),,6,121028,DB01017,Minocycline
,15616299,Systemic clearance,"Systemic clearance ranged from 0.2 to 0.3 liters/h/kg, and the tigecycline half-life ranged from 37 to 67 h.",Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15616299/),[l] / [h·kg],0.2 to 0.3,121812,DB01017,Minocycline
,15616299,half-life,"Systemic clearance ranged from 0.2 to 0.3 liters/h/kg, and the tigecycline half-life ranged from 37 to 67 h.",Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15616299/),h,37 to 67,121813,DB01017,Minocycline
,15616299,volume of distribution,"Tigecycline had a large volume of distribution (7 to 10 liters/kg), indicating extensive distribution into the tissues.",Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15616299/),[l] / [kg],7 to 10,121814,DB01017,Minocycline
,16080071,steady-state maximum concentration,"After a 100-milligram loading dose, followed by 50 milligrams every 12 h, the steady-state maximum concentration in serum after a 1-h infusion is approximately 0.6 microg/mL, the 24-h steady-state area under the concentration-time curve is approximately 5-6 microg.h/mL, and the terminal elimination half-life is approximately 40 h.",The pharmacokinetic and pharmacodynamic profile of tigecycline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16080071/),[μg] / [ml],0.6,137110,DB01017,Minocycline
,16080071,steady-state area under the concentration-time curve,"After a 100-milligram loading dose, followed by 50 milligrams every 12 h, the steady-state maximum concentration in serum after a 1-h infusion is approximately 0.6 microg/mL, the 24-h steady-state area under the concentration-time curve is approximately 5-6 microg.h/mL, and the terminal elimination half-life is approximately 40 h.",The pharmacokinetic and pharmacodynamic profile of tigecycline. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16080071/),[h·μg] / [ml],5-6,137111,DB01017,Minocycline
,16080071,terminal elimination half-life,"After a 100-milligram loading dose, followed by 50 milligrams every 12 h, the steady-state maximum concentration in serum after a 1-h infusion is approximately 0.6 microg/mL, the 24-h steady-state area under the concentration-time curve is approximately 5-6 microg.h/mL, and the terminal elimination half-life is approximately 40 h.",The pharmacokinetic and pharmacodynamic profile of tigecycline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16080071/),h,40,137112,DB01017,Minocycline
,20807146,elimination half-life,The mean+/-SD elimination half-life was 7.70+/-1.91 hours.,Pharmacokinetics and tissue distribution of minocycline hydrochloride in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20807146/),h,7.70,138917,DB01017,Minocycline
,20807146,total body clearance,"The total body clearance was 0.16+/-0.04 L/h/kg, and the volume of distribution at steady state was 1.53+/-0.09 L/kg.",Pharmacokinetics and tissue distribution of minocycline hydrochloride in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20807146/),[l] / [h·kg],0.16,138918,DB01017,Minocycline
,20807146,volume of distribution at steady state,"The total body clearance was 0.16+/-0.04 L/h/kg, and the volume of distribution at steady state was 1.53+/-0.09 L/kg.",Pharmacokinetics and tissue distribution of minocycline hydrochloride in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20807146/),[l] / [kg],1.53,138919,DB01017,Minocycline
,20807146,percentage of plasma protein binding,The percentage of plasma protein binding was 68.1+/-2.6%.,Pharmacokinetics and tissue distribution of minocycline hydrochloride in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20807146/),%,68.1,138920,DB01017,Minocycline
,20807146,Plasma concentration,Plasma concentration of free minocycline was 0.12 microg/mL at 12 hours.,Pharmacokinetics and tissue distribution of minocycline hydrochloride in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20807146/),[μg] / [ml],0.12,138921,DB01017,Minocycline
,22154856,ratio of area under the concentration-time curve/minimum inhibitory concentration (AUC/MIC),The ratio of area under the concentration-time curve/minimum inhibitory concentration (AUC/MIC) for colistin was 158.5 (all three strains) and that for tigecycline was 18.5 (K. pneumoniae NDM) and 37 (K. pneumoniae ATCC 29665 and E. coli NDM).,Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of Klebsiella pneumoniae and Escherichia coli. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22154856/),,158.5,144160,DB01017,Minocycline
,22154856,ratio of area under the concentration-time curve/minimum inhibitory concentration (AUC/MIC),The ratio of area under the concentration-time curve/minimum inhibitory concentration (AUC/MIC) for colistin was 158.5 (all three strains) and that for tigecycline was 18.5 (K. pneumoniae NDM) and 37 (K. pneumoniae ATCC 29665 and E. coli NDM).,Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of Klebsiella pneumoniae and Escherichia coli. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22154856/),,18.5,144161,DB01017,Minocycline
,22154856,ratio of area under the concentration-time curve/minimum inhibitory concentration (AUC/MIC),The ratio of area under the concentration-time curve/minimum inhibitory concentration (AUC/MIC) for colistin was 158.5 (all three strains) and that for tigecycline was 18.5 (K. pneumoniae NDM) and 37 (K. pneumoniae ATCC 29665 and E. coli NDM).,Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of Klebsiella pneumoniae and Escherichia coli. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22154856/),,37,144162,DB01017,Minocycline
,17436824,time of maximum concentration (tmax,"An extended-release (ER) minocycline hydrochloride tablet formulation was developed that demonstrated delayed time of maximum concentration (tmax, 3 1/2 - 4 hours) compared with a nonmodified-release minocycline (tmax, 2 1/4 - 3 hours), and a lower maximum concentration of drug (cmax) in the blood (90%) compared with nonmodified-release formulations.",Key bioavailability features of a new extended-release formulation of minocycline hydrochloride tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17436824/),1,3,145082,DB01017,Minocycline
,17436824,tmax,"An extended-release (ER) minocycline hydrochloride tablet formulation was developed that demonstrated delayed time of maximum concentration (tmax, 3 1/2 - 4 hours) compared with a nonmodified-release minocycline (tmax, 2 1/4 - 3 hours), and a lower maximum concentration of drug (cmax) in the blood (90%) compared with nonmodified-release formulations.",Key bioavailability features of a new extended-release formulation of minocycline hydrochloride tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17436824/),1,2,145083,DB01017,Minocycline
,17436824,0- to 24-hour,"At steady state (day 6), the ER-minocycline formulation had a 0- to 24-hour area under the curve (AUC(0-24)) and cmax of 33.32 microg x h/mL and 2.63 microg/mL, respectively, compared with 46.35 micro x h/mL and 2.92 microg/mL, respectively, for the nonmodified-release minocycline.",Key bioavailability features of a new extended-release formulation of minocycline hydrochloride tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17436824/),[h·μg] / [ml],33.32,145084,DB01017,Minocycline
,17436824,0- to 24-hour,"At steady state (day 6), the ER-minocycline formulation had a 0- to 24-hour area under the curve (AUC(0-24)) and cmax of 33.32 microg x h/mL and 2.63 microg/mL, respectively, compared with 46.35 micro x h/mL and 2.92 microg/mL, respectively, for the nonmodified-release minocycline.",Key bioavailability features of a new extended-release formulation of minocycline hydrochloride tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17436824/),[μg] / [ml],2.63,145085,DB01017,Minocycline
,17436824,0- to 24-hour,"At steady state (day 6), the ER-minocycline formulation had a 0- to 24-hour area under the curve (AUC(0-24)) and cmax of 33.32 microg x h/mL and 2.63 microg/mL, respectively, compared with 46.35 micro x h/mL and 2.92 microg/mL, respectively, for the nonmodified-release minocycline.",Key bioavailability features of a new extended-release formulation of minocycline hydrochloride tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17436824/),[μh] / [ml],46.35,145086,DB01017,Minocycline
,17436824,0- to 24-hour,"At steady state (day 6), the ER-minocycline formulation had a 0- to 24-hour area under the curve (AUC(0-24)) and cmax of 33.32 microg x h/mL and 2.63 microg/mL, respectively, compared with 46.35 micro x h/mL and 2.92 microg/mL, respectively, for the nonmodified-release minocycline.",Key bioavailability features of a new extended-release formulation of minocycline hydrochloride tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17436824/),[μg] / [ml],2.92,145087,DB01017,Minocycline
,17436824,area under the curve (AUC(0-24)),"At steady state (day 6), the ER-minocycline formulation had a 0- to 24-hour area under the curve (AUC(0-24)) and cmax of 33.32 microg x h/mL and 2.63 microg/mL, respectively, compared with 46.35 micro x h/mL and 2.92 microg/mL, respectively, for the nonmodified-release minocycline.",Key bioavailability features of a new extended-release formulation of minocycline hydrochloride tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17436824/),[h·μg] / [ml],33.32,145088,DB01017,Minocycline
,17436824,area under the curve (AUC(0-24)),"At steady state (day 6), the ER-minocycline formulation had a 0- to 24-hour area under the curve (AUC(0-24)) and cmax of 33.32 microg x h/mL and 2.63 microg/mL, respectively, compared with 46.35 micro x h/mL and 2.92 microg/mL, respectively, for the nonmodified-release minocycline.",Key bioavailability features of a new extended-release formulation of minocycline hydrochloride tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17436824/),[μh] / [ml],46.35,145089,DB01017,Minocycline
,17436824,cmax,"At steady state (day 6), the ER-minocycline formulation had a 0- to 24-hour area under the curve (AUC(0-24)) and cmax of 33.32 microg x h/mL and 2.63 microg/mL, respectively, compared with 46.35 micro x h/mL and 2.92 microg/mL, respectively, for the nonmodified-release minocycline.",Key bioavailability features of a new extended-release formulation of minocycline hydrochloride tablets. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17436824/),[μg] / [ml],2.63,145090,DB01017,Minocycline
,17436824,cmax,"At steady state (day 6), the ER-minocycline formulation had a 0- to 24-hour area under the curve (AUC(0-24)) and cmax of 33.32 microg x h/mL and 2.63 microg/mL, respectively, compared with 46.35 micro x h/mL and 2.92 microg/mL, respectively, for the nonmodified-release minocycline.",Key bioavailability features of a new extended-release formulation of minocycline hydrochloride tablets. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17436824/),[μg] / [ml],2.92,145091,DB01017,Minocycline
,15793165,volumes of distribution at steady state,"Except for the volumes of distribution at steady state (approximately 350 liters in women versus 500 liters in men), there were no significant differences in tigecycline pharmacokinetic parameters.",Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15793165/),l,350,145949,DB01017,Minocycline
,15793165,volumes of distribution at steady state,"Except for the volumes of distribution at steady state (approximately 350 liters in women versus 500 liters in men), there were no significant differences in tigecycline pharmacokinetic parameters.",Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15793165/),l,500,145950,DB01017,Minocycline
,27650184,MICs,"Four susceptible isolates (EUCAST MICs of 0.125-1 mg/L) and two intermediately susceptible CP-Kp clinical isolates (MICs of 2 mg/L) were tested at three different inocula (107, 105 and 103 cfu/mL), simulating tigecycline serum and lung fCmax concentrations of 0.15 and 1.5 mg/L, respectively, of 50 mg tigecycline every 12 h for 48 h.",Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650184/),[mg] / [l],0.125-1,148291,DB01017,Minocycline
,27650184,MICs,"Four susceptible isolates (EUCAST MICs of 0.125-1 mg/L) and two intermediately susceptible CP-Kp clinical isolates (MICs of 2 mg/L) were tested at three different inocula (107, 105 and 103 cfu/mL), simulating tigecycline serum and lung fCmax concentrations of 0.15 and 1.5 mg/L, respectively, of 50 mg tigecycline every 12 h for 48 h.",Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650184/),[mg] / [l],2,148292,DB01017,Minocycline
,27650184,fCmax concentrations,"Four susceptible isolates (EUCAST MICs of 0.125-1 mg/L) and two intermediately susceptible CP-Kp clinical isolates (MICs of 2 mg/L) were tested at three different inocula (107, 105 and 103 cfu/mL), simulating tigecycline serum and lung fCmax concentrations of 0.15 and 1.5 mg/L, respectively, of 50 mg tigecycline every 12 h for 48 h.",Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650184/),[mg] / [l],0.15,148293,DB01017,Minocycline
,27650184,fCmax concentrations,"Four susceptible isolates (EUCAST MICs of 0.125-1 mg/L) and two intermediately susceptible CP-Kp clinical isolates (MICs of 2 mg/L) were tested at three different inocula (107, 105 and 103 cfu/mL), simulating tigecycline serum and lung fCmax concentrations of 0.15 and 1.5 mg/L, respectively, of 50 mg tigecycline every 12 h for 48 h.",Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650184/),[mg] / [l],1.5,148294,DB01017,Minocycline
,27650184,MICs,"At lung concentrations and low inocula, a bacteriostatic and killing effect was found for isolates with MICs of 0.25 and 0.125 mg/L, respectively.",Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650184/),[mg] / [l],0.25,148295,DB01017,Minocycline
,27650184,MICs,"At lung concentrations and low inocula, a bacteriostatic and killing effect was found for isolates with MICs of 0.25 and 0.125 mg/L, respectively.",Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650184/),[mg] / [l],0.125,148296,DB01017,Minocycline
,27650184,fAUC0-24/MIC (tAUC0-24/MIC),"The fAUC0-24/MIC (tAUC0-24/MIC) associated with half-maximal activity was 16 (150) with 103 cfu/mL, 28 (239) with 105 cfu/mL and 79 (590) with 107 cfu/mL.",Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650184/),[cfu] / [ml],16,148297,DB01017,Minocycline
,27650184,fAUC0-24/MIC (tAUC0-24/MIC),"The fAUC0-24/MIC (tAUC0-24/MIC) associated with half-maximal activity was 16 (150) with 103 cfu/mL, 28 (239) with 105 cfu/mL and 79 (590) with 107 cfu/mL.",Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650184/),[cfu] / [ml],103,148298,DB01017,Minocycline
,27650184,fAUC0-24/MIC (tAUC0-24/MIC),"The fAUC0-24/MIC (tAUC0-24/MIC) associated with half-maximal activity was 16 (150) with 103 cfu/mL, 28 (239) with 105 cfu/mL and 79 (590) with 107 cfu/mL.",Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650184/),[cfu] / [ml],28,148299,DB01017,Minocycline
,27650184,fAUC0-24/MIC (tAUC0-24/MIC),"The fAUC0-24/MIC (tAUC0-24/MIC) associated with half-maximal activity was 16 (150) with 103 cfu/mL, 28 (239) with 105 cfu/mL and 79 (590) with 107 cfu/mL.",Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650184/),[cfu] / [ml],105,148300,DB01017,Minocycline
,27650184,fAUC0-24/MIC (tAUC0-24/MIC),"The fAUC0-24/MIC (tAUC0-24/MIC) associated with half-maximal activity was 16 (150) with 103 cfu/mL, 28 (239) with 105 cfu/mL and 79 (590) with 107 cfu/mL.",Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650184/),[cfu] / [ml],79,148301,DB01017,Minocycline
,27650184,fAUC0-24/MIC (tAUC0-24/MIC),"The fAUC0-24/MIC (tAUC0-24/MIC) associated with half-maximal activity was 16 (150) with 103 cfu/mL, 28 (239) with 105 cfu/mL and 79 (590) with 107 cfu/mL.",Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650184/),[cfu] / [ml],107,148302,DB01017,Minocycline
,27650184,half-maximal activity,"The fAUC0-24/MIC (tAUC0-24/MIC) associated with half-maximal activity was 16 (150) with 103 cfu/mL, 28 (239) with 105 cfu/mL and 79 (590) with 107 cfu/mL.",Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650184/),[cfu] / [ml],16,148303,DB01017,Minocycline
,27650184,half-maximal activity,"The fAUC0-24/MIC (tAUC0-24/MIC) associated with half-maximal activity was 16 (150) with 103 cfu/mL, 28 (239) with 105 cfu/mL and 79 (590) with 107 cfu/mL.",Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650184/),[cfu] / [ml],28,148304,DB01017,Minocycline
,27650184,half-maximal activity,"The fAUC0-24/MIC (tAUC0-24/MIC) associated with half-maximal activity was 16 (150) with 103 cfu/mL, 28 (239) with 105 cfu/mL and 79 (590) with 107 cfu/mL.",Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650184/),[cfu] / [ml],79,148305,DB01017,Minocycline
,24155157,serum,"Noncompartmental pharmacokinetic analysis serum and bone area under the curve for the given dose interval (AUCτ ) values were 2,402 ng h/mL and 11,465 ng h/g, and maximum concentration (Cmax ) values were 974 ng/mL and 2,262 ng/g, respectively.",Reassessment of tigecycline bone concentrations in volunteers undergoing elective orthopedic procedures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24155157/),[h·ng] / [ml],"2,402",148723,DB01017,Minocycline
,24155157,area under the curve,"Noncompartmental pharmacokinetic analysis serum and bone area under the curve for the given dose interval (AUCτ ) values were 2,402 ng h/mL and 11,465 ng h/g, and maximum concentration (Cmax ) values were 974 ng/mL and 2,262 ng/g, respectively.",Reassessment of tigecycline bone concentrations in volunteers undergoing elective orthopedic procedures. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24155157/),[h·ng] / [ml],"2,402",148724,DB01017,Minocycline
,24155157,area under the curve,"Noncompartmental pharmacokinetic analysis serum and bone area under the curve for the given dose interval (AUCτ ) values were 2,402 ng h/mL and 11,465 ng h/g, and maximum concentration (Cmax ) values were 974 ng/mL and 2,262 ng/g, respectively.",Reassessment of tigecycline bone concentrations in volunteers undergoing elective orthopedic procedures. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24155157/),[h·ng] / [g],"11,465",148725,DB01017,Minocycline
,24155157,maximum concentration (Cmax ),"Noncompartmental pharmacokinetic analysis serum and bone area under the curve for the given dose interval (AUCτ ) values were 2,402 ng h/mL and 11,465 ng h/g, and maximum concentration (Cmax ) values were 974 ng/mL and 2,262 ng/g, respectively.",Reassessment of tigecycline bone concentrations in volunteers undergoing elective orthopedic procedures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24155157/),[ng] / [ml],974,148726,DB01017,Minocycline
,24155157,maximum concentration (Cmax ),"Noncompartmental pharmacokinetic analysis serum and bone area under the curve for the given dose interval (AUCτ ) values were 2,402 ng h/mL and 11,465 ng h/g, and maximum concentration (Cmax ) values were 974 ng/mL and 2,262 ng/g, respectively.",Reassessment of tigecycline bone concentrations in volunteers undergoing elective orthopedic procedures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24155157/),[ng] / [g],"2,262",148727,DB01017,Minocycline
,24155157,bone to serum ratio,"The bone to serum ratio calculated using the AUCτ values was 4.77, confirming tigecycline penetration into bone.",Reassessment of tigecycline bone concentrations in volunteers undergoing elective orthopedic procedures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24155157/),,4.77,148728,DB01017,Minocycline
,15220014,minimum concentration,Values for the minimum concentration of tigecycline that is inhibitory for 90% of all isolates ranged from 0.06 to 0.50 microg/mL for the selected pathogens.,"Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15220014/),[μg] / [ml],0.06 to 0.50,151189,DB01017,Minocycline
,15220014,clinical cure rates,"In patients who received 50-mg doses of tigecycline q12h, the clinical cure rates and microbial eradication rates were 74% and 70%, respectively, and were 67% and 56% in patients who received 25-mg doses.","Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15220014/),%,74,151190,DB01017,Minocycline
,15220014,clinical cure rates,"In patients who received 50-mg doses of tigecycline q12h, the clinical cure rates and microbial eradication rates were 74% and 70%, respectively, and were 67% and 56% in patients who received 25-mg doses.","Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15220014/),%,70,151191,DB01017,Minocycline
,15220014,clinical cure rates,"In patients who received 50-mg doses of tigecycline q12h, the clinical cure rates and microbial eradication rates were 74% and 70%, respectively, and were 67% and 56% in patients who received 25-mg doses.","Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15220014/),%,67,151192,DB01017,Minocycline
,15793157,penetration rate,"Tigecycline penetrates into blister fluid well, with a mean penetration rate of 74%.",Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15793157/),%,74,151281,DB01017,Minocycline
,33168615,free,"Probabilities of achieving the PK-PD targets associated with stasis and 1-log killing (free area under the curve above the MIC [fAUC:MIC] of 12 and 18, respectively) in an immunocompetent animal pneumonia infection model of A. baumannii were evaluated.",Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multicenter Study (ACUMIN). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33168615/),,12,158904,DB01017,Minocycline
,33168615,area under the curve above the MIC [fAUC:MIC],"Probabilities of achieving the PK-PD targets associated with stasis and 1-log killing (free area under the curve above the MIC [fAUC:MIC] of 12 and 18, respectively) in an immunocompetent animal pneumonia infection model of A. baumannii were evaluated.",Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multicenter Study (ACUMIN). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33168615/),,12,158905,DB01017,Minocycline
,33168615,area under the curve above the MIC [fAUC:MIC],"Probabilities of achieving the PK-PD targets associated with stasis and 1-log killing (free area under the curve above the MIC [fAUC:MIC] of 12 and 18, respectively) in an immunocompetent animal pneumonia infection model of A. baumannii were evaluated.",Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multicenter Study (ACUMIN). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33168615/),,18,158906,DB01017,Minocycline
>,33168615,MIC,"In the PK-PD probability of target attainment analyses, minocycline 200 mg i.v. every 12 h (Q12H) was predicted to result in a suboptimal PK-PD profile for patients with A. baumannii infections with MIC values of >1 mg/liter.",Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multicenter Study (ACUMIN). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33168615/),[mg] / [l],1,158907,DB01017,Minocycline
<,11020264,MIC90,The MIC90 of glycylcycline (< or =0.06 mg/L) against 55 strains of Streptococcus pneumoniae was 100-fold lower than that of minocycline or tetracycline.,"Efficacy of a novel tetracycline derivative, glycylcycline, against penicillin-resistant Streptococcus pneumoniae in a mouse model of pneumonia. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11020264/),[mg] / [l],0.06,162410,DB01017,Minocycline
,31039251,MIC,"The MIC for 50% and 90% of cumulative clinical isolates was 8 and 64 mg/L, respectively.",Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31039251/),[mg] / [l],8,165582,DB01017,Minocycline
,31039251,MIC,"The MIC for 50% and 90% of cumulative clinical isolates was 8 and 64 mg/L, respectively.",Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31039251/),[mg] / [l],64,165583,DB01017,Minocycline
,31039251,microbial kill,"In the HFS-MAC model, minocycline achieved a microbial kill of 3.6 log10 cfu/mL below stasis.",Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31039251/),[cfu] / [ml],3.6,165584,DB01017,Minocycline
,31039251,AUC0-24/MIC,The AUC0-24/MIC exposure associated with a bactericidal effect was 59.,Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31039251/),,59,165585,DB01017,Minocycline
,31039251,MIC,Monte Carlo experiments identified a minocycline susceptibility MIC breakpoint of 16 mg/L.,Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31039251/),[mg] / [l],16,165586,DB01017,Minocycline
,4026008,half-life,"Minocycline half-life ranged between 6.48 and 7.24 hours; volume of distribution at steady state, between 1.859 +/- 0.368 and 2.001 +/- 0.468 L/kg; and clearance, between 3.195 +/- 0.618 and 3.424 +/- 0.684 ml/min/kg.",Compartmental and noncompartmental pharmacokinetic analyses of minocycline hydrochloride in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026008/),h,6.48 and 7.24,165831,DB01017,Minocycline
,4026008,volume of distribution at steady state,"Minocycline half-life ranged between 6.48 and 7.24 hours; volume of distribution at steady state, between 1.859 +/- 0.368 and 2.001 +/- 0.468 L/kg; and clearance, between 3.195 +/- 0.618 and 3.424 +/- 0.684 ml/min/kg.",Compartmental and noncompartmental pharmacokinetic analyses of minocycline hydrochloride in the dog. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026008/),[l] / [kg],1.859,165832,DB01017,Minocycline
,4026008,volume of distribution at steady state,"Minocycline half-life ranged between 6.48 and 7.24 hours; volume of distribution at steady state, between 1.859 +/- 0.368 and 2.001 +/- 0.468 L/kg; and clearance, between 3.195 +/- 0.618 and 3.424 +/- 0.684 ml/min/kg.",Compartmental and noncompartmental pharmacokinetic analyses of minocycline hydrochloride in the dog. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026008/),[l] / [kg],2.001,165833,DB01017,Minocycline
,4026008,clearance,"Minocycline half-life ranged between 6.48 and 7.24 hours; volume of distribution at steady state, between 1.859 +/- 0.368 and 2.001 +/- 0.468 L/kg; and clearance, between 3.195 +/- 0.618 and 3.424 +/- 0.684 ml/min/kg.",Compartmental and noncompartmental pharmacokinetic analyses of minocycline hydrochloride in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026008/),[ml] / [kg·min],3.195,165834,DB01017,Minocycline
,4026008,clearance,"Minocycline half-life ranged between 6.48 and 7.24 hours; volume of distribution at steady state, between 1.859 +/- 0.368 and 2.001 +/- 0.468 L/kg; and clearance, between 3.195 +/- 0.618 and 3.424 +/- 0.684 ml/min/kg.",Compartmental and noncompartmental pharmacokinetic analyses of minocycline hydrochloride in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026008/),[ml] / [kg·min],3.424,165835,DB01017,Minocycline
,33841618,trough levels,"Overall, trough levels were approximately 0.5ng/mL from 24 hours after the first dose through 24 hours after the last dose on Day 14, indicating that steady-state levels appear to have been reached within the first day of dosing.",Safety and Pharmacokinetics of FMX103 (1.5% Minocycline Topical Foam) in Subjects with Moderate-to-Severe Papulopustular Rosacea under Maximum-use Treatment Conditions. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33841618/),[ng] / [ml],0.5,177307,DB01017,Minocycline
,17537869,half-life,"After the final dose, the pharmacokinetics of tigecycline in serum showed a long half-life (55.8 h) and a large volume of distribution (21.0 l/kg), whereas radioactivity in serum had a shorter half-life (6.9 h) and a smaller volume of distribution (3.3 l/kg).","Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17537869/),h,55.8,180052,DB01017,Minocycline
,17537869,volume of distribution,"After the final dose, the pharmacokinetics of tigecycline in serum showed a long half-life (55.8 h) and a large volume of distribution (21.0 l/kg), whereas radioactivity in serum had a shorter half-life (6.9 h) and a smaller volume of distribution (3.3 l/kg).","Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17537869/),[l] / [kg],21.0,180053,DB01017,Minocycline
,17537869,half-life,"After the final dose, the pharmacokinetics of tigecycline in serum showed a long half-life (55.8 h) and a large volume of distribution (21.0 l/kg), whereas radioactivity in serum had a shorter half-life (6.9 h) and a smaller volume of distribution (3.3 l/kg).","Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17537869/),h,6.9,180054,DB01017,Minocycline
,17537869,volume of distribution,"After the final dose, the pharmacokinetics of tigecycline in serum showed a long half-life (55.8 h) and a large volume of distribution (21.0 l/kg), whereas radioactivity in serum had a shorter half-life (6.9 h) and a smaller volume of distribution (3.3 l/kg).","Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17537869/),[l] / [kg],3.3,180055,DB01017,Minocycline
,19998582,AUC(t),"The mean AUC(t), AUC(inf), C(max), and t were 18038.55 ng x h x mL(-1), 19648.21 ng x h x mL(-1), 1076.01 ng x mL(-1), and 17.33 h, respectively, for the test drug and 17979.43 ng x h x mL(-1), 19639.78 ng x h x mL(-1), 1095.97 ng x mL(-1), and 16.44 h, respectively, for the reference drug.",Bioequivalence study of two minocycline capsule formulations in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998582/),[h·ng] / [ml],18038.55,193242,DB01017,Minocycline
,19998582,AUC(inf),"The mean AUC(t), AUC(inf), C(max), and t were 18038.55 ng x h x mL(-1), 19648.21 ng x h x mL(-1), 1076.01 ng x mL(-1), and 17.33 h, respectively, for the test drug and 17979.43 ng x h x mL(-1), 19639.78 ng x h x mL(-1), 1095.97 ng x mL(-1), and 16.44 h, respectively, for the reference drug.",Bioequivalence study of two minocycline capsule formulations in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998582/),[h·ng] / [ml],19648.21,193243,DB01017,Minocycline
,19998582,AUC(inf),"The mean AUC(t), AUC(inf), C(max), and t were 18038.55 ng x h x mL(-1), 19648.21 ng x h x mL(-1), 1076.01 ng x mL(-1), and 17.33 h, respectively, for the test drug and 17979.43 ng x h x mL(-1), 19639.78 ng x h x mL(-1), 1095.97 ng x mL(-1), and 16.44 h, respectively, for the reference drug.",Bioequivalence study of two minocycline capsule formulations in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998582/),[ng] / [ml],1076.01,193244,DB01017,Minocycline
,19998582,C(max),"The mean AUC(t), AUC(inf), C(max), and t were 18038.55 ng x h x mL(-1), 19648.21 ng x h x mL(-1), 1076.01 ng x mL(-1), and 17.33 h, respectively, for the test drug and 17979.43 ng x h x mL(-1), 19639.78 ng x h x mL(-1), 1095.97 ng x mL(-1), and 16.44 h, respectively, for the reference drug.",Bioequivalence study of two minocycline capsule formulations in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998582/),[h·ng] / [ml],19648.21,193245,DB01017,Minocycline
,19998582,C(max),"The mean AUC(t), AUC(inf), C(max), and t were 18038.55 ng x h x mL(-1), 19648.21 ng x h x mL(-1), 1076.01 ng x mL(-1), and 17.33 h, respectively, for the test drug and 17979.43 ng x h x mL(-1), 19639.78 ng x h x mL(-1), 1095.97 ng x mL(-1), and 16.44 h, respectively, for the reference drug.",Bioequivalence study of two minocycline capsule formulations in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998582/),[ng] / [ml],1076.01,193246,DB01017,Minocycline
,19998582,t,"The mean AUC(t), AUC(inf), C(max), and t were 18038.55 ng x h x mL(-1), 19648.21 ng x h x mL(-1), 1076.01 ng x mL(-1), and 17.33 h, respectively, for the test drug and 17979.43 ng x h x mL(-1), 19639.78 ng x h x mL(-1), 1095.97 ng x mL(-1), and 16.44 h, respectively, for the reference drug.",Bioequivalence study of two minocycline capsule formulations in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998582/),h,17.33,193247,DB01017,Minocycline
,19998582,t,"The mean AUC(t), AUC(inf), C(max), and t were 18038.55 ng x h x mL(-1), 19648.21 ng x h x mL(-1), 1076.01 ng x mL(-1), and 17.33 h, respectively, for the test drug and 17979.43 ng x h x mL(-1), 19639.78 ng x h x mL(-1), 1095.97 ng x mL(-1), and 16.44 h, respectively, for the reference drug.",Bioequivalence study of two minocycline capsule formulations in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998582/),h,16.44,193248,DB01017,Minocycline
,19998582,t(max),"The median (range) of t(max) of the test drug and reference drug were 2.0 (1.0-4.0) h and 2.0 (0.67-4.0) h, respectively.",Bioequivalence study of two minocycline capsule formulations in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998582/),h,2.0,193249,DB01017,Minocycline
,19998582,t(max),"The median (range) of t(max) of the test drug and reference drug were 2.0 (1.0-4.0) h and 2.0 (0.67-4.0) h, respectively.",Bioequivalence study of two minocycline capsule formulations in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998582/),h,2.0,193250,DB01017,Minocycline
,28833289,bioavailability,"The bioavailability of TIG after i.m., s.c., and p.o. administration was 32.59 ± 5.99%, 34.91 ± 9.62%, and 0.97 ± 0.57%, respectively.",Pharmacokinetics of tigecycline in turkeys following different routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28833289/),%,32.59,199436,DB01017,Minocycline
,28833289,bioavailability,"The bioavailability of TIG after i.m., s.c., and p.o. administration was 32.59 ± 5.99%, 34.91 ± 9.62%, and 0.97 ± 0.57%, respectively.",Pharmacokinetics of tigecycline in turkeys following different routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28833289/),%,34.91,199437,DB01017,Minocycline
,28833289,bioavailability,"The bioavailability of TIG after i.m., s.c., and p.o. administration was 32.59 ± 5.99%, 34.91 ± 9.62%, and 0.97 ± 0.57%, respectively.",Pharmacokinetics of tigecycline in turkeys following different routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28833289/),%,0.97,199438,DB01017,Minocycline
,28833289,half-life in the elimination phase,"Values of half-life in the elimination phase were 23.49 ± 6.51 hr, 25.42 ± 4.42 hr, and 26.62 ± 5.19 hr in i.v., i.m., and s.c. groups, respectively, values of mean residence time were 7.92 ± 1.41 hr, 19.62 ± 2.82 hr, and 17.55 ± 2.59 hr in i.v., i.m., and s.c. groups, respectively, whereas the volume of distribution was 14.85 ± 5.71 L/kg, 14.68 ± 2.56 L/kg, and 15.37 ± 3.00 L/kg in i.v., i.m., and s.c. groups, respectively.",Pharmacokinetics of tigecycline in turkeys following different routes of administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28833289/),h,23.49,199439,DB01017,Minocycline
,28833289,half-life in the elimination phase,"Values of half-life in the elimination phase were 23.49 ± 6.51 hr, 25.42 ± 4.42 hr, and 26.62 ± 5.19 hr in i.v., i.m., and s.c. groups, respectively, values of mean residence time were 7.92 ± 1.41 hr, 19.62 ± 2.82 hr, and 17.55 ± 2.59 hr in i.v., i.m., and s.c. groups, respectively, whereas the volume of distribution was 14.85 ± 5.71 L/kg, 14.68 ± 2.56 L/kg, and 15.37 ± 3.00 L/kg in i.v., i.m., and s.c. groups, respectively.",Pharmacokinetics of tigecycline in turkeys following different routes of administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28833289/),h,25.42,199440,DB01017,Minocycline
,28833289,half-life in the elimination phase,"Values of half-life in the elimination phase were 23.49 ± 6.51 hr, 25.42 ± 4.42 hr, and 26.62 ± 5.19 hr in i.v., i.m., and s.c. groups, respectively, values of mean residence time were 7.92 ± 1.41 hr, 19.62 ± 2.82 hr, and 17.55 ± 2.59 hr in i.v., i.m., and s.c. groups, respectively, whereas the volume of distribution was 14.85 ± 5.71 L/kg, 14.68 ± 2.56 L/kg, and 15.37 ± 3.00 L/kg in i.v., i.m., and s.c. groups, respectively.",Pharmacokinetics of tigecycline in turkeys following different routes of administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28833289/),h,26.62,199441,DB01017,Minocycline
,28833289,mean residence time,"Values of half-life in the elimination phase were 23.49 ± 6.51 hr, 25.42 ± 4.42 hr, and 26.62 ± 5.19 hr in i.v., i.m., and s.c. groups, respectively, values of mean residence time were 7.92 ± 1.41 hr, 19.62 ± 2.82 hr, and 17.55 ± 2.59 hr in i.v., i.m., and s.c. groups, respectively, whereas the volume of distribution was 14.85 ± 5.71 L/kg, 14.68 ± 2.56 L/kg, and 15.37 ± 3.00 L/kg in i.v., i.m., and s.c. groups, respectively.",Pharmacokinetics of tigecycline in turkeys following different routes of administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28833289/),h,7.92,199442,DB01017,Minocycline
,28833289,mean residence time,"Values of half-life in the elimination phase were 23.49 ± 6.51 hr, 25.42 ± 4.42 hr, and 26.62 ± 5.19 hr in i.v., i.m., and s.c. groups, respectively, values of mean residence time were 7.92 ± 1.41 hr, 19.62 ± 2.82 hr, and 17.55 ± 2.59 hr in i.v., i.m., and s.c. groups, respectively, whereas the volume of distribution was 14.85 ± 5.71 L/kg, 14.68 ± 2.56 L/kg, and 15.37 ± 3.00 L/kg in i.v., i.m., and s.c. groups, respectively.",Pharmacokinetics of tigecycline in turkeys following different routes of administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28833289/),h,19.62,199443,DB01017,Minocycline
,28833289,mean residence time,"Values of half-life in the elimination phase were 23.49 ± 6.51 hr, 25.42 ± 4.42 hr, and 26.62 ± 5.19 hr in i.v., i.m., and s.c. groups, respectively, values of mean residence time were 7.92 ± 1.41 hr, 19.62 ± 2.82 hr, and 17.55 ± 2.59 hr in i.v., i.m., and s.c. groups, respectively, whereas the volume of distribution was 14.85 ± 5.71 L/kg, 14.68 ± 2.56 L/kg, and 15.37 ± 3.00 L/kg in i.v., i.m., and s.c. groups, respectively.",Pharmacokinetics of tigecycline in turkeys following different routes of administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28833289/),h,17.55,199444,DB01017,Minocycline
,28833289,volume of distribution,"Values of half-life in the elimination phase were 23.49 ± 6.51 hr, 25.42 ± 4.42 hr, and 26.62 ± 5.19 hr in i.v., i.m., and s.c. groups, respectively, values of mean residence time were 7.92 ± 1.41 hr, 19.62 ± 2.82 hr, and 17.55 ± 2.59 hr in i.v., i.m., and s.c. groups, respectively, whereas the volume of distribution was 14.85 ± 5.71 L/kg, 14.68 ± 2.56 L/kg, and 15.37 ± 3.00 L/kg in i.v., i.m., and s.c. groups, respectively.",Pharmacokinetics of tigecycline in turkeys following different routes of administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28833289/),[l] / [kg],14.85,199445,DB01017,Minocycline
,28833289,volume of distribution,"Values of half-life in the elimination phase were 23.49 ± 6.51 hr, 25.42 ± 4.42 hr, and 26.62 ± 5.19 hr in i.v., i.m., and s.c. groups, respectively, values of mean residence time were 7.92 ± 1.41 hr, 19.62 ± 2.82 hr, and 17.55 ± 2.59 hr in i.v., i.m., and s.c. groups, respectively, whereas the volume of distribution was 14.85 ± 5.71 L/kg, 14.68 ± 2.56 L/kg, and 15.37 ± 3.00 L/kg in i.v., i.m., and s.c. groups, respectively.",Pharmacokinetics of tigecycline in turkeys following different routes of administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28833289/),[l] / [kg],14.68,199446,DB01017,Minocycline
,28833289,volume of distribution,"Values of half-life in the elimination phase were 23.49 ± 6.51 hr, 25.42 ± 4.42 hr, and 26.62 ± 5.19 hr in i.v., i.m., and s.c. groups, respectively, values of mean residence time were 7.92 ± 1.41 hr, 19.62 ± 2.82 hr, and 17.55 ± 2.59 hr in i.v., i.m., and s.c. groups, respectively, whereas the volume of distribution was 14.85 ± 5.71 L/kg, 14.68 ± 2.56 L/kg, and 15.37 ± 3.00 L/kg in i.v., i.m., and s.c. groups, respectively.",Pharmacokinetics of tigecycline in turkeys following different routes of administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28833289/),[l] / [kg],15.37,199447,DB01017,Minocycline
,21163728,volume of distribution,Daptomycin has a very small volume of distribution of 7L indicating very little tissue distribution whereas tigecycline has a very large volume of distribution of 350-500 L.,"Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21163728/),l,7,200704,DB01017,Minocycline
,21163728,volume of distribution,Daptomycin has a very small volume of distribution of 7L indicating very little tissue distribution whereas tigecycline has a very large volume of distribution of 350-500 L.,"Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21163728/),l,350-500,200705,DB01017,Minocycline
,21163728,volumes of distribution,"Vancomycin and linezolid are in-between with volumes of distribution of approximately 30 and 50 L, close to total body water.","Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21163728/),l,30,200706,DB01017,Minocycline
,21163728,volumes of distribution,"Vancomycin and linezolid are in-between with volumes of distribution of approximately 30 and 50 L, close to total body water.","Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21163728/),l,50,200707,DB01017,Minocycline
,21163728,half-lives,"Although the elimination pathways are very different, the resulting half-lives of linezolid, vancomycin, and daptomycin are not greatly different and vary from 4-8 h.","Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21163728/),h,4-8,200708,DB01017,Minocycline
up to,21163728,half-life,"Tigecycline, however, has a much longer half-life of up to 1-2 days due to the slow redistribution from tissue binding sites.","Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21163728/),d,1-2,200709,DB01017,Minocycline
,20179255,penetration ratio,"The calculated tigecycline penetration ratio in this patient ranged from 0% to 52%, depending on the calculation methodology utilized.",Cerebral spinal fluid penetration of tigecycline in a patient with Acinetobacter baumannii cerebritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20179255/),%,0,204537,DB01017,Minocycline
,20179255,penetration ratio,"The calculated tigecycline penetration ratio in this patient ranged from 0% to 52%, depending on the calculation methodology utilized.",Cerebral spinal fluid penetration of tigecycline in a patient with Acinetobacter baumannii cerebritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20179255/),%,52,204538,DB01017,Minocycline
,9624555,prostatic tissue/serum ratio,"Although amikacin showed the highest mean concentration both in prostatic tissue and prostatic fluid, the prostatic tissue/serum ratio was significantly higher (P < 0.01) for ofloxacin (1.49 +/- 0.80) and minocycline (0.94 +/- 0.39) compared with those for amikacin (0.49 +/- 0.21) and piperacillin (0.21 +/- 0.15).","Diffusion of piperacillin, cefotiam, minocycline, amikacin and ofloxacin into the prostate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9624555/),,1,216034,DB01017,Minocycline
,9624555,prostatic tissue/serum ratio,"Although amikacin showed the highest mean concentration both in prostatic tissue and prostatic fluid, the prostatic tissue/serum ratio was significantly higher (P < 0.01) for ofloxacin (1.49 +/- 0.80) and minocycline (0.94 +/- 0.39) compared with those for amikacin (0.49 +/- 0.21) and piperacillin (0.21 +/- 0.15).","Diffusion of piperacillin, cefotiam, minocycline, amikacin and ofloxacin into the prostate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9624555/),,0,216035,DB01017,Minocycline
,16105560,terminal elimination half-life,"Pharmacokinetic analysis of data from phase 1 trials of healthy subjects indicate that tigecycline has a large volume of distribution, signifying extensive tissue penetration, and a long terminal elimination half-life (approximately 40 h), easily allowing for twice-daily dose administration.",Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16105560/),h,40,216167,DB01017,Minocycline
,21797013,flow rate,"A Hypersil BDS RP-C18 column (250 x 4.6 mm, 5 microm particle size) was used with the mobile phase phosphate buffer (pH 7.10, 0.070 M)-acetonitrile (76 + 24, v/v) at a flow rate of 1.0 mL/min.",Robust and sensitive high-performance liquid chromatographic-UV detection technique for the determination of tigecycline in rabbit plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21797013/),[ml] / [min],1.0,219954,DB01017,Minocycline
,21797013,elution time,"The elution time of tigecycline and minocycline was approximately 8.1 and 9.9 min, respectively.",Robust and sensitive high-performance liquid chromatographic-UV detection technique for the determination of tigecycline in rabbit plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21797013/),min,8.1,219955,DB01017,Minocycline
,21797013,elution time,"The elution time of tigecycline and minocycline was approximately 8.1 and 9.9 min, respectively.",Robust and sensitive high-performance liquid chromatographic-UV detection technique for the determination of tigecycline in rabbit plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21797013/),min,9.9,219956,DB01017,Minocycline
,21797013,LOD,"The LOD and LOQ in plasma were estimated as 7 and 21 ng/mL, respectively.",Robust and sensitive high-performance liquid chromatographic-UV detection technique for the determination of tigecycline in rabbit plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21797013/),[ng] / [ml],7,219957,DB01017,Minocycline
,21797013,LOQ,"The LOD and LOQ in plasma were estimated as 7 and 21 ng/mL, respectively.",Robust and sensitive high-performance liquid chromatographic-UV detection technique for the determination of tigecycline in rabbit plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21797013/),[ng] / [ml],21,219958,DB01017,Minocycline
,19696049,penetration ratio,"The group without pulmonary infection displayed an ELF penetration ratio of 8.1 and 6.2 for the 50 and 25 mg/kg doses, respectively.",Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19696049/),,8.1,220067,DB01017,Minocycline
,19696049,penetration ratio,"The group without pulmonary infection displayed an ELF penetration ratio of 8.1 and 6.2 for the 50 and 25 mg/kg doses, respectively.",Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19696049/),,6.2,220068,DB01017,Minocycline
,19696049,penetration ratios,The respective penetration ratios in the infected lungs were 23.3 and 12.9.,Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19696049/),,23.3,220069,DB01017,Minocycline
,19696049,penetration ratios,The respective penetration ratios in the infected lungs were 23.3 and 12.9.,Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19696049/),,12.9,220070,DB01017,Minocycline
,791106,heat production,"When the antibiotic was present from the start of the experiment, a heat production of 2.0 muW/ml was registered after 12.5 h using minocycline; the corresponding figures for doxycycline, oxytetracycline, and tetracycline were 7.3, 6.6, and 4.5 h, respectively.",Kinetics of the actions of tetracyclines on Escherichia coli as studied by microcalorimetry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/791106/),[muw] / [ml],2.0,221556,DB01017,Minocycline
,791106,heat production,"When the antibiotic was present from the start of the experiment, a heat production of 2.0 muW/ml was registered after 12.5 h using minocycline; the corresponding figures for doxycycline, oxytetracycline, and tetracycline were 7.3, 6.6, and 4.5 h, respectively.",Kinetics of the actions of tetracyclines on Escherichia coli as studied by microcalorimetry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/791106/),h,7.3,221557,DB01017,Minocycline
,791106,heat production,"When the antibiotic was present from the start of the experiment, a heat production of 2.0 muW/ml was registered after 12.5 h using minocycline; the corresponding figures for doxycycline, oxytetracycline, and tetracycline were 7.3, 6.6, and 4.5 h, respectively.",Kinetics of the actions of tetracyclines on Escherichia coli as studied by microcalorimetry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/791106/),h,6.6,221558,DB01017,Minocycline
,791106,heat production,"When the antibiotic was present from the start of the experiment, a heat production of 2.0 muW/ml was registered after 12.5 h using minocycline; the corresponding figures for doxycycline, oxytetracycline, and tetracycline were 7.3, 6.6, and 4.5 h, respectively.",Kinetics of the actions of tetracyclines on Escherichia coli as studied by microcalorimetry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/791106/),h,4.5,221559,DB01017,Minocycline
,791106,MIC,"The MIC for all the tetracyclines tested, determined by the broth dilution technique, was 0.8 mug/ml.",Kinetics of the actions of tetracyclines on Escherichia coli as studied by microcalorimetry. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/791106/),[μg] / [ml],0.8,221560,DB01017,Minocycline
,28677837,flow rate,"The analyte and IS were separated on a reversed-phase Waters Acquity UPLC® BEH-C18 column (2.1 × 50 mm i.d., 1.7 μm) with a flow rate of 0.25 mL/min.",Determination of tigecycline in human plasma by LC-MS/MS and its application to population pharmacokinetics study in Chinese patients with hospital-acquired pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28677837/),[ml] / [min],0.25,223128,DB01017,Minocycline
,28891075,bioavailability,Mean ± SD bioavailability (fasted: 38.6% ± 4.6; fed: 15.7% ± 2.3) and Cmax (fasted: 1.343 ± 0.418 μg/ml; fed: 0.281 ± 0.157 μg/ml) were greater in fasted horses compared to fed horses (p < .05 both).,Effect of feeding on the pharmacokinetics of oral minocycline in healthy adult horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28891075/),%,38.6,225487,DB01017,Minocycline
,28891075,bioavailability,Mean ± SD bioavailability (fasted: 38.6% ± 4.6; fed: 15.7% ± 2.3) and Cmax (fasted: 1.343 ± 0.418 μg/ml; fed: 0.281 ± 0.157 μg/ml) were greater in fasted horses compared to fed horses (p < .05 both).,Effect of feeding on the pharmacokinetics of oral minocycline in healthy adult horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28891075/),%,15.7,225488,DB01017,Minocycline
,28891075,Cmax,Mean ± SD bioavailability (fasted: 38.6% ± 4.6; fed: 15.7% ± 2.3) and Cmax (fasted: 1.343 ± 0.418 μg/ml; fed: 0.281 ± 0.157 μg/ml) were greater in fasted horses compared to fed horses (p < .05 both).,Effect of feeding on the pharmacokinetics of oral minocycline in healthy adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28891075/),[μg] / [ml],1.343,225489,DB01017,Minocycline
,28891075,Cmax,Mean ± SD bioavailability (fasted: 38.6% ± 4.6; fed: 15.7% ± 2.3) and Cmax (fasted: 1.343 ± 0.418 μg/ml; fed: 0.281 ± 0.157 μg/ml) were greater in fasted horses compared to fed horses (p < .05 both).,Effect of feeding on the pharmacokinetics of oral minocycline in healthy adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28891075/),[μg] / [ml],0.281,225490,DB01017,Minocycline
,28891075,Tmax,Median (range) Tmax (hr) in fasted horses was 2.0 (1.5-3.5) and in fed horses was 5.0 (1.0-8.0) and was not significantly different between groups.,Effect of feeding on the pharmacokinetics of oral minocycline in healthy adult horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28891075/),h,2.0,225491,DB01017,Minocycline
,28891075,Tmax,Median (range) Tmax (hr) in fasted horses was 2.0 (1.5-3.5) and in fed horses was 5.0 (1.0-8.0) and was not significantly different between groups.,Effect of feeding on the pharmacokinetics of oral minocycline in healthy adult horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28891075/),h,5.0,225492,DB01017,Minocycline
,12543655,MIC,"The tigecycline MIC at which 50% of strains are inhibited for 101 different Legionella sp. strains was 4 micro g/ml versus 0.125 and 0.25 micro g/ml for azithromycin and erythromycin, respectively.",Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12543655/),[μg] / [ml],4,226343,DB01017,Minocycline
,12543655,MIC,"The tigecycline MIC at which 50% of strains are inhibited for 101 different Legionella sp. strains was 4 micro g/ml versus 0.125 and 0.25 micro g/ml for azithromycin and erythromycin, respectively.",Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12543655/),[μg] / [ml],0.125,226344,DB01017,Minocycline
,12543655,MIC,"The tigecycline MIC at which 50% of strains are inhibited for 101 different Legionella sp. strains was 4 micro g/ml versus 0.125 and 0.25 micro g/ml for azithromycin and erythromycin, respectively.",Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12543655/),[μg] / [ml],0.25,226345,DB01017,Minocycline
,12543655,peak serum,"When tigecycline was given (7.5 mg/kg of body weight subcutaneously once) to guinea pigs with L. pneumophila pneumonia, the mean peak serum and lung levels were 2.3 and 1.8 micro g/ml (1.2 and 1.5 micro g/g) at 1 and 2 h postinjection, respectively.",Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12543655/),[μg] / [ml],2.3,226346,DB01017,Minocycline
,12543655,lung levels,"When tigecycline was given (7.5 mg/kg of body weight subcutaneously once) to guinea pigs with L. pneumophila pneumonia, the mean peak serum and lung levels were 2.3 and 1.8 micro g/ml (1.2 and 1.5 micro g/g) at 1 and 2 h postinjection, respectively.",Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12543655/),[μg] / [ml],1.8,226347,DB01017,Minocycline
,12543655,lung levels,"When tigecycline was given (7.5 mg/kg of body weight subcutaneously once) to guinea pigs with L. pneumophila pneumonia, the mean peak serum and lung levels were 2.3 and 1.8 micro g/ml (1.2 and 1.5 micro g/g) at 1 and 2 h postinjection, respectively.",Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12543655/),[μg] / [g],1.2,226348,DB01017,Minocycline
,12543655,lung levels,"When tigecycline was given (7.5 mg/kg of body weight subcutaneously once) to guinea pigs with L. pneumophila pneumonia, the mean peak serum and lung levels were 2.3 and 1.8 micro g/ml (1.2 and 1.5 micro g/g) at 1 and 2 h postinjection, respectively.",Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12543655/),[μg] / [g],1.5,226349,DB01017,Minocycline
,12543655,areas under the concentration time curve from 0 to 24 h,"The serum and lung areas under the concentration time curve from 0 to 24 h were 13.7 and 15.8 micro g. h/ml, respectively.",Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12543655/),[h·μg] / [ml],15.8,226350,DB01017,Minocycline
,12543655,lung,"Tigecycline-treated guinea pigs had average end of therapy lung counts of 1 x 10(6) CFU/g (range, 2.5 x 10(4) to 3.2 x 10(6) CFU/g) versus <1 x 10(2) CFU/g for azithromycin (range, undetectable to 100 CFU/g).",Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12543655/),[cfu] / [g],1 x 10,226351,DB01017,Minocycline
,20308689,clearance,"Mean (± 1 SD) tigecycline clearance values were 29.8 ± 11.3 L/h in healthy subjects and 31.2 ± 13.9 L/h (Child-Pugh A), 22.1 ± 9.3 L/h (Child-Pugh B), and 13.5 ± 2.7 L/h (Child-Pugh C) in the patients.",Pharmacokinetics and safety of a single intravenous dose of the antibiotic tigecycline in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20308689/),[l] / [h],29.8,227549,DB01017,Minocycline
,20308689,clearance,"Mean (± 1 SD) tigecycline clearance values were 29.8 ± 11.3 L/h in healthy subjects and 31.2 ± 13.9 L/h (Child-Pugh A), 22.1 ± 9.3 L/h (Child-Pugh B), and 13.5 ± 2.7 L/h (Child-Pugh C) in the patients.",Pharmacokinetics and safety of a single intravenous dose of the antibiotic tigecycline in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20308689/),[l] / [h],31.2,227550,DB01017,Minocycline
,20308689,clearance,"Mean (± 1 SD) tigecycline clearance values were 29.8 ± 11.3 L/h in healthy subjects and 31.2 ± 13.9 L/h (Child-Pugh A), 22.1 ± 9.3 L/h (Child-Pugh B), and 13.5 ± 2.7 L/h (Child-Pugh C) in the patients.",Pharmacokinetics and safety of a single intravenous dose of the antibiotic tigecycline in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20308689/),[l] / [h],22.1,227551,DB01017,Minocycline
,20308689,clearance,"Mean (± 1 SD) tigecycline clearance values were 29.8 ± 11.3 L/h in healthy subjects and 31.2 ± 13.9 L/h (Child-Pugh A), 22.1 ± 9.3 L/h (Child-Pugh B), and 13.5 ± 2.7 L/h (Child-Pugh C) in the patients.",Pharmacokinetics and safety of a single intravenous dose of the antibiotic tigecycline in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20308689/),[l] / [h],13.5,227552,DB01017,Minocycline
,19399726,absorption,"Moreover, their absorption is highly variable and incomplete, ranging usually from 25 % to 60 % (absorption of tetracycline ranges from 77 % to 88 %).",[Pharmacokinetics of tetracyclines and glycylcyclines]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19399726/),%,77,228006,DB01017,Minocycline
,19399726,absorption,"Moreover, their absorption is highly variable and incomplete, ranging usually from 25 % to 60 % (absorption of tetracycline ranges from 77 % to 88 %).",[Pharmacokinetics of tetracyclines and glycylcyclines]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19399726/),%,88,228007,DB01017,Minocycline
more,19399726,bioavailability,"Doxycycline, the most common member of this group, features more than 80 % bioavailability.",[Pharmacokinetics of tetracyclines and glycylcyclines]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19399726/),%,80,228008,DB01017,Minocycline
,3802746,percent penetration,Tetracycline penetrated into the lymph better than minocycline (percent penetration 67.3% of cf. 38.2%).,Ovine pulmonary transit of tetracycline and minocycline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802746/),%,67.3,235845,DB01017,Minocycline
,3802746,percent penetration,Tetracycline penetrated into the lymph better than minocycline (percent penetration 67.3% of cf. 38.2%).,Ovine pulmonary transit of tetracycline and minocycline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802746/),%,38.2,235846,DB01017,Minocycline
,24811802,MIC,97% isolates displayed susceptibility and 3% were tigecycline-intermediate strains and the values of MIC ranged from 0.125 to 4 μ g/ml.,A pharmacodynamic simulation to evaluate tigecycline in treatment of nosocomial pneumonia caused by multidrug-resistant Acinetobacter baumannii. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24811802/),[g·μ] / [ml],0.125 to 4,237128,DB01017,Minocycline
,10674962,TC,"The average concentrations at 2 h were highest in plasma (TC = 1.02, MN=2.18, DX=2.35 microg/ml).","Concentration of 3 tetracyclines in plasma, gingival crevice fluid and saliva. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10674962/),[μg] / [ml],1.02,237666,DB01017,Minocycline
,10674962,MN,"The average concentrations at 2 h were highest in plasma (TC = 1.02, MN=2.18, DX=2.35 microg/ml).","Concentration of 3 tetracyclines in plasma, gingival crevice fluid and saliva. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10674962/),[μg] / [ml],2.18,237667,DB01017,Minocycline
,10674962,MN,"The average concentrations at 2 h were highest in plasma (TC = 1.02, MN=2.18, DX=2.35 microg/ml).","Concentration of 3 tetracyclines in plasma, gingival crevice fluid and saliva. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10674962/),[μg] / [ml],2.35,237668,DB01017,Minocycline
,10674962,TC,"Saliva concentrations (TC=0.09 MN=0.31, DX=0.47 microg/ml) were the lowest of the 3 fluids monitored.","Concentration of 3 tetracyclines in plasma, gingival crevice fluid and saliva. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10674962/),,0.09,237669,DB01017,Minocycline
,10674962,DX,"Saliva concentrations (TC=0.09 MN=0.31, DX=0.47 microg/ml) were the lowest of the 3 fluids monitored.","Concentration of 3 tetracyclines in plasma, gingival crevice fluid and saliva. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10674962/),[μg] / [ml],0.47,237670,DB01017,Minocycline
,26863149,Oral bioavailability,"Oral bioavailability of eravacycline is estimated at 28 % (range 26-32 %) and a single oral dose of 200 mg achieves a maximum plasma concentration (C max) and area under the plasma concentration-time curve from 0 to infinity (AUC0-∞) of 0.23 ± 0.04 mg/L and 3.34 ± 1.11 mg·h/L, respectively.","Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26863149/),%,28,250081,DB01017,Minocycline
,26863149,maximum plasma concentration (C max),"Oral bioavailability of eravacycline is estimated at 28 % (range 26-32 %) and a single oral dose of 200 mg achieves a maximum plasma concentration (C max) and area under the plasma concentration-time curve from 0 to infinity (AUC0-∞) of 0.23 ± 0.04 mg/L and 3.34 ± 1.11 mg·h/L, respectively.","Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26863149/),[mg] / [l],0.23,250082,DB01017,Minocycline
,26863149,area under the plasma concentration-time curve from 0 to infinity (AUC0-∞),"Oral bioavailability of eravacycline is estimated at 28 % (range 26-32 %) and a single oral dose of 200 mg achieves a maximum plasma concentration (C max) and area under the plasma concentration-time curve from 0 to infinity (AUC0-∞) of 0.23 ± 0.04 mg/L and 3.34 ± 1.11 mg·h/L, respectively.","Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26863149/),[h·mg] / [l],3.34,250083,DB01017,Minocycline
,26863149,steady-state volume of distribution (V ss),"A population pharmacokinetic study of intravenous (IV) eravacycline demonstrated a mean steady-state volume of distribution (V ss) of 320 L or 4.2 L/kg, a mean terminal elimination half-life (t ½) of 48 h, and a mean total clearance (CL) of 13.5 L/h.","Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26863149/),l,320,250084,DB01017,Minocycline
,26863149,steady-state volume of distribution (V ss),"A population pharmacokinetic study of intravenous (IV) eravacycline demonstrated a mean steady-state volume of distribution (V ss) of 320 L or 4.2 L/kg, a mean terminal elimination half-life (t ½) of 48 h, and a mean total clearance (CL) of 13.5 L/h.","Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26863149/),[l] / [kg],4.2,250085,DB01017,Minocycline
,26863149,terminal elimination half-life (t ½),"A population pharmacokinetic study of intravenous (IV) eravacycline demonstrated a mean steady-state volume of distribution (V ss) of 320 L or 4.2 L/kg, a mean terminal elimination half-life (t ½) of 48 h, and a mean total clearance (CL) of 13.5 L/h.","Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26863149/),h,48,250086,DB01017,Minocycline
,26863149,total clearance (CL),"A population pharmacokinetic study of intravenous (IV) eravacycline demonstrated a mean steady-state volume of distribution (V ss) of 320 L or 4.2 L/kg, a mean terminal elimination half-life (t ½) of 48 h, and a mean total clearance (CL) of 13.5 L/h.","Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26863149/),[l] / [h],13.5,250087,DB01017,Minocycline
,12499194,MICs,MICs of GAR-936 were 0.06 micro g/ml for the three strains.,Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12499194/),[μg] / [ml],0.06,250833,DB01017,Minocycline
,12499194,serum elimination half-life,Mean serum elimination half-life ranged from 3.3 to 3.6 h.,Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12499194/),h,3.3 to 3.6,250834,DB01017,Minocycline
,15977966,apparent volume of distribution,Administration of a 100mg loading dose of tigecycline followed by twice-daily doses of 50mg yielded an apparent volume of distribution of 7-10 L/kg.,Tigecycline: a novel glycylcycline. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15977966/),[l] / [kg],7-10,254329,DB01017,Minocycline
,15977966,Systemic clearance,Systemic clearance ranged from 0.2 to 0.3 L/h/kg and its half-life varied from 37 to 67 hours.,Tigecycline: a novel glycylcycline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15977966/),[l] / [h·kg],0.2 to 0.3,254330,DB01017,Minocycline
,15977966,half-life,Systemic clearance ranged from 0.2 to 0.3 L/h/kg and its half-life varied from 37 to 67 hours.,Tigecycline: a novel glycylcycline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15977966/),h,37 to 67,254331,DB01017,Minocycline
,18519719,MICs,"The minocycline MICs for these four strains were 0.04 mg/liter, 0.19 mg/liter, 0.06 mg/liter, and 0.75 mg/liter.",Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519719/),[mg] / [l],0.04,254724,DB01017,Minocycline
,18519719,MICs,"The minocycline MICs for these four strains were 0.04 mg/liter, 0.19 mg/liter, 0.06 mg/liter, and 0.75 mg/liter.",Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519719/),[mg] / [l],0.19,254725,DB01017,Minocycline
,18519719,MICs,"The minocycline MICs for these four strains were 0.04 mg/liter, 0.19 mg/liter, 0.06 mg/liter, and 0.75 mg/liter.",Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519719/),[mg] / [l],0.06,254726,DB01017,Minocycline
,18519719,MICs,"The minocycline MICs for these four strains were 0.04 mg/liter, 0.19 mg/liter, 0.06 mg/liter, and 0.75 mg/liter.",Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519719/),[mg] / [l],0.75,254727,DB01017,Minocycline
<,18519719,MICs,"Minocycline alone produced a 1.5- to 2.0-log(10)-unit reduction in viable count for the strains with MICs of <0.2 mg/liter, while the addition of rifampin increased the ABE for these strains (P < 0.05).",Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519719/),[mg] / [l],0.2,254728,DB01017,Minocycline
,18519719,AUC/MIC ratios,"Free area under the concentration-time curve (AUC)/MIC was best related to AUBKC or d24 using a sigmoid maximal effect (Emax) model with r(2) of 0.92 and 0.87, respectively, and the AUC/MIC ratios for no change and -1-log-unit, -2-log-unit, and -3-log-unit drop at 24 h were 33.9, 75.9, 1,350, and >2,000, respectively.",Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519719/),,33.9,254729,DB01017,Minocycline
,18519719,AUC/MIC ratios,"Free area under the concentration-time curve (AUC)/MIC was best related to AUBKC or d24 using a sigmoid maximal effect (Emax) model with r(2) of 0.92 and 0.87, respectively, and the AUC/MIC ratios for no change and -1-log-unit, -2-log-unit, and -3-log-unit drop at 24 h were 33.9, 75.9, 1,350, and >2,000, respectively.",Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519719/),,75.9,254730,DB01017,Minocycline
,18519719,AUC/MIC ratios,"Free area under the concentration-time curve (AUC)/MIC was best related to AUBKC or d24 using a sigmoid maximal effect (Emax) model with r(2) of 0.92 and 0.87, respectively, and the AUC/MIC ratios for no change and -1-log-unit, -2-log-unit, and -3-log-unit drop at 24 h were 33.9, 75.9, 1,350, and >2,000, respectively.",Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519719/),,"1,350",254731,DB01017,Minocycline
,18519719,AUC/MIC ratios,"Free area under the concentration-time curve (AUC)/MIC was best related to AUBKC or d24 using a sigmoid maximal effect (Emax) model with r(2) of 0.92 and 0.87, respectively, and the AUC/MIC ratios for no change and -1-log-unit, -2-log-unit, and -3-log-unit drop at 24 h were 33.9, 75.9, 1,350, and >2,000, respectively.",Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519719/),,"2,000",254732,DB01017,Minocycline
,22136488,serum peak,"The mean serum peak and trough concentrations of tigecycline were 0.56±0.25 mg/L and 0.26±0.12 mg/L, respectively.",Tigecycline penetration into skin and soft tissue. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22136488/),[mg] / [l],0.56,255079,DB01017,Minocycline
,22136488,trough concentrations,"The mean serum peak and trough concentrations of tigecycline were 0.56±0.25 mg/L and 0.26±0.12 mg/L, respectively.",Tigecycline penetration into skin and soft tissue. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22136488/),[mg] / [l],0.26,255080,DB01017,Minocycline
,22136488,tissue:serum ratios,"The mean tissue:serum ratios at the three study time periods were 3.8 (range 0.7-5.5), 5.2 (range 0.8-7.1), and 2.8 (range 0.8-8.8).",Tigecycline penetration into skin and soft tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22136488/),,3.8,255081,DB01017,Minocycline
,22136488,tissue:serum ratios,"The mean tissue:serum ratios at the three study time periods were 3.8 (range 0.7-5.5), 5.2 (range 0.8-7.1), and 2.8 (range 0.8-8.8).",Tigecycline penetration into skin and soft tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22136488/),,5.2,255082,DB01017,Minocycline
,22136488,tissue:serum ratios,"The mean tissue:serum ratios at the three study time periods were 3.8 (range 0.7-5.5), 5.2 (range 0.8-7.1), and 2.8 (range 0.8-8.8).",Tigecycline penetration into skin and soft tissue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22136488/),,2.8,255083,DB01017,Minocycline
,28887388,time to peak concentration (Tmax),"Although the literature supports a time to peak concentration (Tmax) of 1 hour for oral minocycline, the Tmax was estimated to be at least 6 hours in this cohort.",Minocycline in Acute Cerebral Hemorrhage: An Early Phase Randomized Trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28887388/),h,1,255848,DB01017,Minocycline
,28887388,Tmax,"Although the literature supports a time to peak concentration (Tmax) of 1 hour for oral minocycline, the Tmax was estimated to be at least 6 hours in this cohort.",Minocycline in Acute Cerebral Hemorrhage: An Early Phase Randomized Trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28887388/),h,6,255849,DB01017,Minocycline
,28887388,elimination half-life,The elimination half-life (available on 7 patients) was 17.5 hours (SD±3.5).,Minocycline in Acute Cerebral Hemorrhage: An Early Phase Randomized Trial. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28887388/),h,17.5,255850,DB01017,Minocycline
,17012300,ratio of AUC(0-24),"Tissue penetration, expressed as the ratio of AUC(0-24) in tissue or body fluid to serum, was 537 for bile, 23 for gall bladder, 2.6 for colon, 2.0 for lung, 0.41 for bone, 0.31 for SF and 0.11 for CSF.","Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17012300/),,537,260634,DB01017,Minocycline
,17012300,ratio of AUC(0-24),"Tissue penetration, expressed as the ratio of AUC(0-24) in tissue or body fluid to serum, was 537 for bile, 23 for gall bladder, 2.6 for colon, 2.0 for lung, 0.41 for bone, 0.31 for SF and 0.11 for CSF.","Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17012300/),,23,260635,DB01017,Minocycline
,17012300,ratio of AUC(0-24),"Tissue penetration, expressed as the ratio of AUC(0-24) in tissue or body fluid to serum, was 537 for bile, 23 for gall bladder, 2.6 for colon, 2.0 for lung, 0.41 for bone, 0.31 for SF and 0.11 for CSF.","Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17012300/),,2.6,260636,DB01017,Minocycline
,17012300,ratio of AUC(0-24),"Tissue penetration, expressed as the ratio of AUC(0-24) in tissue or body fluid to serum, was 537 for bile, 23 for gall bladder, 2.6 for colon, 2.0 for lung, 0.41 for bone, 0.31 for SF and 0.11 for CSF.","Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17012300/),,2.0,260637,DB01017,Minocycline
,17012300,ratio of AUC(0-24),"Tissue penetration, expressed as the ratio of AUC(0-24) in tissue or body fluid to serum, was 537 for bile, 23 for gall bladder, 2.6 for colon, 2.0 for lung, 0.41 for bone, 0.31 for SF and 0.11 for CSF.","Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17012300/),,0,260638,DB01017,Minocycline
,28705678,area under the unbound drug concentration-time curve to minimum inhibitory concentration ratio (fAUC/MIC),The mean ± standard deviation area under the unbound drug concentration-time curve to minimum inhibitory concentration ratio (fAUC/MIC) associated with a 24-h bacteriostatic effect was 16.4 ± 2.6 and with a -1 log reduction in bacterial load at 24 h was 23.3 ± 3.7.,Pharmacodynamics of minocycline against Acinetobacter baumannii studied in a pharmacokinetic model of infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28705678/),,16.4,269002,DB01017,Minocycline
>,28705678,fAUC/MIC ratios,"Changes in population profiles were noted for two of the three strains studied, especially at fAUC/MIC ratios of >5-15.",Pharmacodynamics of minocycline against Acinetobacter baumannii studied in a pharmacokinetic model of infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28705678/),,5-15,269003,DB01017,Minocycline
,28705678,fAUC/MIC,A reasonable translational pharmacodynamic target for MNO against A. baumannii could be an fAUC/MIC of 20-25.,Pharmacodynamics of minocycline against Acinetobacter baumannii studied in a pharmacokinetic model of infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28705678/),,20-25,269004,DB01017,Minocycline
,28607024,clearance (CL),"The parameter estimates (expressed as means ± standard deviations [SD]) from the final model were as follows: clearance (CL), 7.50 ± 1.11 liters/h; volume in the central compartment, 72.50 ± 21.18 liters; rate constant for tigecycline distribution from the central to the peripheral compartment, 0.31 ± 0.16 h-1; and rate constant for tigecycline distribution from the peripheral to the central compartment, 0.29 ± 0.30 h-1 A larger BMI was associated with increased CL of tigecycline.",Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28607024/),[l] / [h],7.50,270031,DB01017,Minocycline
,28607024,volume in the central compartment,"The parameter estimates (expressed as means ± standard deviations [SD]) from the final model were as follows: clearance (CL), 7.50 ± 1.11 liters/h; volume in the central compartment, 72.50 ± 21.18 liters; rate constant for tigecycline distribution from the central to the peripheral compartment, 0.31 ± 0.16 h-1; and rate constant for tigecycline distribution from the peripheral to the central compartment, 0.29 ± 0.30 h-1 A larger BMI was associated with increased CL of tigecycline.",Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28607024/),l,72.50,270032,DB01017,Minocycline
,28607024,rate constant,"The parameter estimates (expressed as means ± standard deviations [SD]) from the final model were as follows: clearance (CL), 7.50 ± 1.11 liters/h; volume in the central compartment, 72.50 ± 21.18 liters; rate constant for tigecycline distribution from the central to the peripheral compartment, 0.31 ± 0.16 h-1; and rate constant for tigecycline distribution from the peripheral to the central compartment, 0.29 ± 0.30 h-1 A larger BMI was associated with increased CL of tigecycline.",Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28607024/),1/[h],0.31,270033,DB01017,Minocycline
,28607024,rate constant,"The parameter estimates (expressed as means ± standard deviations [SD]) from the final model were as follows: clearance (CL), 7.50 ± 1.11 liters/h; volume in the central compartment, 72.50 ± 21.18 liters; rate constant for tigecycline distribution from the central to the peripheral compartment, 0.31 ± 0.16 h-1; and rate constant for tigecycline distribution from the peripheral to the central compartment, 0.29 ± 0.30 h-1 A larger BMI was associated with increased CL of tigecycline.",Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28607024/),1/[h],0.29,270034,DB01017,Minocycline
,28607024,AUC0-24/MIC target,"Licensed doses were found to be sufficient for Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, and methicillin-resistant Staphylococcus aureus for an AUC0-24/MIC target of 4.5 or 6.96.",Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28607024/),,4.5,270035,DB01017,Minocycline
,28607024,AUC0-24/MIC target,"Licensed doses were found to be sufficient for Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, and methicillin-resistant Staphylococcus aureus for an AUC0-24/MIC target of 4.5 or 6.96.",Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28607024/),,6.96,270036,DB01017,Minocycline
